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ABSTRACT
Transdermal drug delivery offers many advantages over traditional drug delivery
methods. However, the natural resistance of the skin to drug permeation represents a major
challenge that transdermal drug delivery needs to overcome in a safe and reversible manner. One
method for enhancing transdermal drug delivery involves the application of ultrasound (US) to
skin to physically overcome the skin's barrier properties. To advance this method, the focus of
this thesis has been to develop novel experimental strategies and data analyses that can be
utilized in in vitro investigations of passive and US-enhanced transdermal drug delivery.
US treatment is often combined with a chemical enhancer such as the surfactant sodium
lauryl sulfate (SLS). The simultaneous application of US and SLS (referred to as US/SLS) to
skin exhibits synergism in enhancing transdermal drug delivery and has been utilized in clinical
settings. In order to study the delivery of therapeutic macromolecules into US/SLS-treated skin,
e.g. vaccine delivery to the Langerhans cells or drug delivery to the blood capillaries near the
epidermis-dermis junction, it would be desirable to conduct in vitro US/SLS-enhanced
transdermal diffusion experiments using split-thickness skin (STS) models, in which much of the
dermis is removed in order to simulate the in vivo transdermal diffusion to the desired skin
component. Therefore, STS was evaluated as an alternative to the well-established US/SLS-
treated full-thickness skin (FTS) model for the delivery of hydrophilic permeants. The skin
permeabilities and the aqueous pore radii of US/SLS-treated pig FTS, 700-pm-thick pig STS,
human FTS, 700-pm-thick human STS, and 250-pm-thick human STS were compared over a
range of skin electrical resistivity values. The US/SLS-treated pig skin models were found to
exhibit similar permeabilities and pore radii, but the human skin models did not. Furthermore,
the US/SLS-enhanced delivery of gold nanoparticles and quantum dots (two model hydrophilic
macromolecules) was found to be greater through pig STS than through pig FTS, due to the
presence of less dermis that acts as an artificial barrier to macromolecules. In spite of greater
variability in correlations between STS permeability and resistivity, the results strongly suggest
the use of 700-pm-thick pig STS to investigate the in vitro US/SLS-enhanced delivery of
hydrophilic macromolecules.
After the validation of the pig STS for US/SLS studies, this skin model was used to study
the transdermal delivery of nanoparticles. While nanoparticles have potential as transdermal drug
carriers, many studies have shown that nanoparticle skin penetration is limited. Therefore, the
US/SLS treatment was evaluated as a skin pre-treatment method for enhancing the passive
transdermal delivery of nanoparticles. Quantitative and qualitative methods (elemental analysis
and confocal microscopy, respectively) were utilized to compare the delivery of 10-nm and 20-
nm cationic, neutral, and anionic quantum dots into US/SLS-treated and untreated pig STS. The
findings include: (a) ~0.01% of the quantum dots penetrated the dermis of untreated skin (which
was quantified for the first time), (b) the quantum dots fully permeated US/SLS-treated skin, (c)
the two cationic quantum dots studied exhibited different extents of skin penetration and dermal
clearance, and (d) the quantum dot skin penetration is heterogeneous (which was determined
using a novel application of confocal microscopy). Routes of nanoparticle skin penetration are
discussed, as well as the application of the methods described herein to address conflicting
literature reports on nanoparticle skin penetration in the context of nanoparticle skin toxicity.
US/SLS treatment is concluded to significantly enhance quantum dot transdermal penetration by
500 - 1300%. The findings suggest that an optimum surface charge exists for nanoparticle skin
penetration, and motivate the application of nanoparticle carriers to US/SLS-treated skin for
enhanced transdermal drug delivery.
The final investigation of this thesis focused on chemical penetration enhancers, which
are used to enhance drug delivery through several biological membranes, particularly the stratum
corneum of the skin. However, the fundamental mechanisms that govern the interactions
between penetration enhancers and membranes are not fully understood. Therefore, the goal of
this work was to identify naturally fluorescent penetration enhancers (FPEs) in order to utilize
well-established fluorescence techniques to directly study the behavior of FPEs within the skin.
In this study, 12 FPE candidates were selected and ranked according to their potency as skin
penetration enhancers. The best FPEs found compared well to SLS, a well-known potent skin
penetration enhancer. Based on the ranking of the FPEs, FPE design principles are presented. In
addition, to illustrate the novel, direct, and non-invasive visualization of the behavior of FPEs
within skin, three case studies involving the use of two-photon fluorescence microscopy are
presented, including visualizing glycerol-mitigated and US-enhanced FPE skin penetration.
Previous two-photon fluorescence microscopy studies have indirectly visualized the effect of
penetration enhancers on skin by using a fluorescent permeant to probe the transdermal pathways
of the penetration enhancer. These effects can now be directly visualized and investigated using
FPEs. The combination of FPEs with fluorescence techniques represents a useful new approach
for elucidating the mechanisms involved in penetration enhancement and membrane irritation,
and for improving structure-activity relationships for penetration enhancers. The new physical
insights obtained using FPEs will aid in designing effective penetration enhancers for drug
delivery applications, including penetration enhancers to be combined with US for
synergistically enhancing transdermal drug delivery.
The experimental strategies presented in this thesis pave the way for investigations in
several transdermal fields, including evaluating nanoparticle skin toxicity, designing nanoparticle
drug delivery carriers, evaluating ultrasound-assisted transdermal vaccination, elucidating
mechanisms of chemical penetration enhancer-induced skin irritation, designing topical
formulations with penetration enhancers, and elucidating mechanisms of ultrasound and
penetration enhancer synergism in enhancing skin permeability.
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CHAPTER 1
INTRODUCTION
1.1 OVERVIEW OF TRANSDERMAL DRUG DELIVERY
Transdermal drug delivery offers many advantages over traditional drug delivery
methods, including oral delivery and injections. Delivery through the skin circumvents problems
associated with the acidic environment of the stomach, liver metabolism, and absorption in the
gastrointestinal tract [1,2]. Furthermore, transdermal drug delivery provides a non-invasive,
minimal-pain alternative to injections, resulting in higher levels of patient compliance.
Unfortunately, transdermal drug delivery has its own disadvantages. A major challenge that
transdermal drug delivery needs to overcome in a safe and reversible manner is the natural
resistance of the skin to drug permeation. At the start of this thesis work in December 2006, only
15 hydrophobic drug molecules (all with molecular weights of less than 400 Daltons) had FDA
approval for therapeutic applications using transdermal delivery methods [3-6]. Currently, there
are 19 drugs available in the form of a transdermal patch.
1.2 IMPACT OF SKIN STRUCTURE ON TRANSDERMAL DRUG DELIVERY
The reason why the skin is such a good protective barrier can be understood by
examining the unique structure of the skin. The three main layers of the skin are the stratum
corneum, the viable epidermis, and the dermis (see FIGURE 1-1). The stratum corneum, the
outermost layer, is the thinnest layer of the skin with a thickness of 10 - 20 ptm in humans, while
the viable epidermis and the dermis have thicknesses of 100 - 200 pm and 1 - 4 mm,
respectively [7]. The stratum corneum typically consists of 15 offset layers of flat, interlocking,
polyhedral corneocytes (dead skin cells filled with cross-linked keratin fibers) surrounded by a
matrix of lipid bilayers. The stratum corneum structure has been compared to that of a brick wall,
where the anucleated cells are the "bricks" and the intercellular lipids are the "mortar" (see
FIGURE 1-2). This tightly packed brick-and-mortar structure is the primary barrier to transdermal
diffusion.
Stratum Comeum (10 -20 ptm)
- Viable Epidermis (100 - 200 pim)
. Blood Capillaries
~ ~ ~~ ~ ~~ Dermis (1000 - 4000 pm)
FIGURE 1-1: Sketch of the cross-section of the skin. The three main layers of the skin are the
stratum corneum, the viable epidermis, and the dermis (figure adapted from [8]).
FIGURE 1-2: Schematic representation of the brick-and-mortar model of the stratum corneum.
Corneocytes (depicted in gray) are shown with their characteristic hexagonal shape and are
contained within the lipid bilayers (depicted in white). In humans, the stratum corneum has a
thickness of 10 - 20 pm and typically consists of 15 interlocking layers of corneocytes (figure
adapted from [9]).
1.3 METHODS TO ENHANCE TRANSDERMAL DRUG DELIVERY
To increase skin permeability, recent advances in transdermal drug delivery have focused
on: (1) disrupting the highly ordered stratum corneum, (2) providing a driving force in addition
to a chemical gradient across the skin, or (3) bypassing the stratum corneum. Such methods
include: (i) electroporation, (ii) iontophoresis, (iii) chemical enhancers, (iv) microneedles, (v)
laser-ablation, and (vi) sonophoresis. Briefly, electroporation creates temporary pores in the skin
through the application of pulsed electric voltages, increasing the area available for permeant
diffusion [10]. Iontophoresis enhances transdermal drug delivery for charged molecules by
applying an electric field across the skin [10,11]. Chemical enhancers can enhance transdermal
drug delivery by several mechanisms [12], including: (a) disrupting the lipid bilayers and the
connective proteins of the stratum comeum [13], (b) interacting with keratin to denature it or to
modify its conformation [14], (c) improving the drug partitioning between the donor solution and
the stratum corneum [15], and (d) enhancing drug solubility in the donor solution [16].
Microneedles are short, thin needles that are designed to penetrate into the epidermis, effectively
bypassing the stratum corneum [17]. In this case, the injections are pain-free because the
microneedles do not penetrate into the dermis, the skin layer with nerves [17]. Laser-ablation
removes the stratum corneum from the desired drug delivery site [18]. Sonophoresis, the
transdermal drug delivery enhancement method that is the focus of this thesis, utilizes ultrasound
to make the stratum corneum more permeable. Each of the above enhancement methods has
yielded successful results in increasing the skin permeability in order to facilitate drug transport.
Additionally, combinations of these enhancement methods have been attempted with some
synergistic effects observed, resulting in even greater enhancements of transdermal drug delivery
[15,19-23]. One of the more interesting synergistic effects was observed by combining
sonophoresis and chemical enhancers, which will be discussed in more detail in Section 1.4.5.
1.4 SONOPHORESIS
1.4.1 ULTRASOUND (US) BASICS
Sound is created by a mechanical vibration that is transmitted through a medium such
that the particles in the medium vibrate. All the particles in the medium oscillate between regions
of low and high pressure. The pressure cycle that these particles experience can be characterized
by amplitude and frequency (see FIGuRE 1-3). Sound waves with frequencies > 20 kHz are
collectively referred to as ultrasound (US). Various US frequencies have been utilized to enhance
transdermal drug delivery. These frequencies are typically divided into three ranges: low
frequency (20 - 100 kHz), therapeutic (0.7 - 3 MHz), and high frequency (> 3 MHz).
Pressure Amplitude
Time
1/Frequency
FIGURE 1-3: A sound wave, or a pressure wave, can be characterized by amplitude and
frequency.
1.4.2 MECHANISMS OF US ENHANCEMENT
Low-frequency US has been shown to be most effective for enhancing transdermal drug
delivery [24,25]. Mechanistically, low-frequency US induces acoustic cavitation bubble
formation in the coupling medium between the US horn and the skin [26,27]. The implosion of
the cavitation bubbles in the coupling medium near the skin surface leads to the onset of violent
shockwaves that can disrupt the skin structure [26,27]. These shockwaves are accompanied by
the onset of microjets that are directed toward the skin surface, which drives the coupling
medium into the skin [26,27]. Additionally, US creates acoustic streaming in the coupling
medium [26,27]. All of these mechanisms contribute to enhancing skin permeability, with
cavitation being the main contributor [26,27]. For a more thorough discussion on the
mechanisms of US enhancement, the reader is referred to [27].
1.4.3 LOCALIZED TRANSPORT REGIONS IN US-TREATED SKIN
Interestingly, US treatment does not result in uniform skin permeability enhancement
across the entire skin surface [27,28]. It is now well-established that US treatment creates areas
of significantly higher permeability than the surrounding regions. These regions are referred to as
localized transport regions (LTRs) and non-LTRs, respectively. They can be visualized when a
dye is included in the coupling medium during US treatment (see FIGURE 1-4). It has recently
been proposed that LTRs are regions above which cavitation-induced microjet collapses
occurred, and that non-LTRs are regions of enhanced skin permeability resulting from acoustic
streaming [29].
non-LTR
LTRs
FIGURE 1-4: Localized transport regions (LTRs) and non-LTRs on the surface of pig skin treated
with 20 kHz ultrasound and 40% ethanol (a chemical enhancer). The LTRs are stained with red
food coloring.
1.4.4 MOTIVATION FOR US-ENHANCED TRANSDERMAL DRUG DELIVERY
There are several attributes of sonophoresis that are advantageous for transdermal drug
delivery. Specifically: (i) sonophoresis can enhance the delivery of a broad class of permeants,
including hydrophobic and hydrophilic permeants and macromolecules [27,30], (ii) sonophoresis
is non-invasive (there is no physical device, such as a needle, that penetrates the skin), (iii)
sonophoresis treatment parameters, such as US frequency, intensity, and application time, can be
varied to control the degree of skin permeability enhancement needed for topical or systemic
deliveries [19,31-33], (iv) sonophoresis has been demonstrated in the clinic to be a patient-
friendly treatment; it can be applied to the skin as a brief, pain-free treatment on the order of 10
seconds, prior to the application of a drug-loaded transdermal patch [34-36], and (v)
sonophoresis is FDA-approved for transdermal drug delivery [37] (discussed further in Section
1.4.7).
1.4.5 US SYNERGISM WITH CHEMICAL ENHANCERS
Sonophoresis and chemical enhancers can be simultaneously applied to skin by including
chemical enhancers in the coupling medium during US treatment. Without US, chemical
enhancers can permeabilize skin by fluidizing or extracting the lipid bilayers of the stratum
corneum and by denaturing the corneocytes. However, the extent of skin permeabilization is
limited by the ability of the chemical enhancers to penetrate the skin. As mentioned in Section
1.4.2, US drives the coupling medium into the skin. Therefore, when chemical enhancers are
included in the coupling medium, the US assists in the penetration of the chemical enhancers into
the skin and their subsequent dispersion in the skin. The combination of these methods increases
skin permeability to a greater extent than either method alone [23].
1.4.6 US SYNERGISM WITH SURFACTANTS
The synergism between US and chemical enhancers has been shown to be particularly
significant for surfactants [21]. Surfactants are a unique subset of chemical enhancers because
they preferentially adsorb at interfaces. Therefore, surfactants are not only present in the bulk
coupling medium that is driven into the skin via microjets; they are also adsorbed onto the
air/liquid interface of cavitation bubbles as the bubbles collapse towards the skin. Therefore, US
more effectively assists with the penetration of surfactants into the skin relative to that of other
chemical enhancers [38].
1.4.7 MOTIVATION FOR US/SLS TREATMENT
Several types of surfactants have been applied to skin simultaneously with US [21]. The
most common surfactant combined with sonophoresis is sodium lauryl sulfate (SLS), a common
anionic surfactant that is also known as sodium dodecyl sulfate (SDS). The combination of US
and SLS treatments (referred to hereafter as US/SLS) has even been used in several clinical
studies [30]. US/SLS was first applied to expedite the topical delivery of lidocaine, reducing the
time of onset of numbness from 30 - 60 minutes to < 5 minutes [36]. A device for self-
administration of US/SLS was developed by Sontra Medical (now Echo Therapeutics). This
device, called SonoPrep, was FDA approved for use in both adults and children to expedite the
onset of anesthesia prior to hypodermic injection, intravenous cannulation, and blood donation
[35,36,39-41]. Clinical studies were also conducted to evaluate the technology for the continuous
extraction of interstitial fluid for blood glucose monitoring [34]. This application is exciting
because it can be coupled with insulin administration to create an automated transdermal system
for the continuous treatment of diabetes. Likely due to the clinical validation of this technique,
several groups have been investigating US/SLS for enhancing transdermal drug delivery. This
technique is the method of choice for studying enhanced transdermal drug delivery in this thesis.
1.5 THESIS OBJECTIVES
The unifying theme throughout my thesis work has been to advance the transdermal field
by developing novel experimental strategies and data analyses that can be utilized in in vitro
investigations of passive and US-enhanced transdermal drug delivery. The following specific
objectives were carried out:
i. Evaluated split-thickness skin as an alternative in vitro skin model to full-thickness skin
for investigating the US-enhanced delivery of hydrophilic permeants.
ii. Demonstrated the use of complementary, sensitive, quantitative and qualitative methods
for evaluating the passive and US-enhanced transdermal delivery of nanoparticles.
iii. Identified novel fluorescent penetration enhancers in order to utilize fluorescence
technologies to directly visualize their behavior within skin.
1.6 THEsIS OVERVIEW
Following a description of the primary equipment used in this thesis, presented in
Chapter 2, Chapters 3 - 5 describe studies on developing new strategies for investigating passive
and US-enhanced transdermal drug delivery. Specifically, in Chapter 3, the split-thickness skin
(STS) model, which is a common in vitro skin model used to investigate passive transdermal
drug delivery, was evaluated as an alternative skin model for investigating US/SLS-enhanced
transdermal drug delivery. Prior to this study, all in vitro investigations in US/SLS-enhanced
transdermal drug delivery had been carried out using full-thickness skin (FTS). In order to study
the delivery of therapeutic macromolecules into US/SLS-treated skin, to the Langerhans cells or
to the blood capillaries at the epidermis-dermis junction, it is desirable to conduct in vitro
US/SLS-enhanced transdermal diffusion experiments using STS models, in which much of the
dermis is removed in order to simulate the in vivo transdermal diffusion to the desired skin
component. The motivation for this work was to show that FTS and STS undergo similar extents
of skin structural perturbation in response to the US/SLS treatment, a combined mechanical and
chemical skin permeability enhancement method, in spite of the fact that the two skin models
differ in mechanical strength because of the thinner portion of dermis present in STS.
Chapter 4 describes an investigation aimed at enhancing the potential of rigid
nanoparticles to serve as transdermal drug carriers by improving their skin penetration using
US/SLS treatment. In this study, two experimental techniques - elemental analysis and confocal
fluorescence microscopy - were combined to quantitatively and qualitatively investigate the
delivery of nanoparticle drug carriers into US/SLS-treated skin and untreated skin (which is
quantified for the first time). In addition, the combination of quantitative and qualitative methods
presented here is proposed to clarify some of the controversies reported in the literature
regarding the transdermal penetration of nanoparticles and nanoparticle skin toxicity.
Chapter 5 focuses on chemical penetration enhancers, which are used to enhance drug
delivery through several biological membranes, particularly the stratum corneum of the skin.
Prior to this study, the effect of penetration enhancers on skin structure could only be evaluated
indirectly. In addition, the fundamental mechanisms that govern the interactions between
penetration enhancers and membranes have not been fully elucidated. Therefore, the goal of this
work was to identify naturally fluorescent penetration enhancers in order to utilize well-
established fluorescence techniques to directly visualize the behavior of penetration enhancers
within the skin.
Finally, in Chapter 6, the contributions and impact of this thesis is summarized, and
detailed recommendations are offered for future studies.
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CHAPTER 2
PRIMARY EQUIPMENT
The main purpose of this chapter is to show figures of the primary equipment used in this
thesis in order to aid the reader in understanding how the experiments were performed. In
addition, the basic principles underlying the use of the equipment are discussed in order to aid
the reader in interpreting the results presented in subsequent chapters.
2.1 FRANZ DIFFUSION CELL
A Franz diffusion cell consists of a donor chamber and a receiver chamber, with a skin
sample mounted between the two chambers (see FIGURE 2-1). A clamp is used to hold the
apparatus together. Electrodes are positioned above and below the skin and the chambers are
filled with an aqueous solution in order to measure the skin electrical resistivity. A stirbar may
be included to mix the receiver solution during skin permeability measurements. During
ultrasound treatment, an ultrasound probe tip (see Section 2.2) is lowered into the donor chamber
such that the tip is immersed in a coupling medium between the tip and the skin.
FIGURE 2-1: Franz diffusion cell.
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2.2 ULTRASOUND EQUIPMENT
FIGURE 2-2: Ultrasound equipment.
The ultrasound equipment consists of a signal generator, converter, and probe (see
FIGURE 2-2). On the signal generator, the ultrasound application time, pulse mode, and amplitude
(which is related to the ultrasound intensity) can be specified. The electrical signal is transmitted
to a piezoelectric transducer within the converter, where the signal is converted into a
mechanical vibration. The probe amplifies the vibration generated by the converter. During
ultrasound application, the probe tip is immersed in a coupling medium and is positioned at a
specified distance from the skin sample (mounted into a Franz diffusion cell and supported by a
diffusion cell holder).
2.3 DERMATOME
FIGURE 2-3: Dermatome.
A dermatome (see FIGURE 2-3) can be thought of as a large razor that is used to shave off
a specified thickness of skin from a full-thickness skin sample in order to reduce the thickness of
the dermis layer (see FIGURE 2-4). The top layer of skin that is "shaved off' is referred to as
dermatomed, or split-thickness, skin.
Epidermis
Blood Capillaries
Dermis
1.0 - 2.5 mm
Full-Thickness Skin
0.25 - 0.75 mm
Dermatomed, or Split-Thickness, Skin
FIGURE 2-4: Comparison of skin thickness with and without dermatoming.
2.4 LIQUID SCINTILLATION COUNTER
Computer
FIGURE 2-5: Liquid scintillation counter (figure from [42]).
A liquid scintillation counter (see FIGURE 2-5) is used to measure the radioactivity of a
sample. Prior to loading sample vials into the liquid scintillation counter, scintillation cocktail is
added to the vials. The scintillation cocktail absorbs radioactive emissions and emits
fluorescence, thereby converting radioactivity into light, or scintillations. The liquid scintillation
counter has a computer-automated conveyor system so that many samples can be counted after a
single loading. Each vial is automatically placed in a dark counting chamber where a
photomultiplier tube counts the scintillations.
2.5 CONFOCAL AND Two-PHOTON FLUORESCENCE MICROSCOPY
FIGURE 2-6: Confocal and two-photon fluorescence microscopy system.
Confocal and two-photon fluorescence microscopy are used to non-invasively acquire
fluorescence images from selected depths within tissue (a process referred to as optical
sectioning). The Zeiss LSM 510 system shown in FIGURE 2-6 is equipped for both confocal and
two-photon microscopy. The sample is loaded onto the microscope, and various settings can be
adjusted in order to acquire a confocal or two-photon image. Images are acquired one pixel at a
time. For a two-dimensional image, each pixel is recorded by a computer as the laser scans over
the entire plane of interest. A three-dimensional image can be generated by assembling a stack of
two-dimensional images from scanning successive focal planes.
For each pixel, a laser is focused by an objective lens onto a focal point within the
sample. The subsequent fluorescence (along with scattered light and reflected laser light) is then
collected by the objective lens. A series of mirrors, filters, and pinholes are used to isolate the
desired fluorescence originating from the focal point. In addition, the sample fluorescence beam
can be split by wavelength and sent to separate photomultiplier tubes in order to separately detect
various colors of fluorescence originating from the focal point.
The basic principles of confocal and two-photon microscopy are different. For confocal
microscopy, the laser that is utilized consists of photons of sufficient energy to excite the
fluorophores within the sample. By focusing the laser beam onto a focal point, most of the
fluorescence collected by the objective lens originates from the focal point, and fluorescence
from outside of the focal point can be physically excluded through the use of a pinhole. For two-
photon microscopy, the laser consists of photons of roughly half of the energy required to excite
the sample. Therefore, a fluorophore must simultaneously absorb two photons in order to
fluoresce. Within the focal point, the photon density is sufficiently high to generate significant
amounts of two-photon-excited fluorescence. Outside of the focal point, where the photon
density is lower, the number of two-photon absorption events is very small. Therefore, two-
photon microscopy is more efficient than confocal microscopy and does not require a pinhole to
block fluorescence from outside of the focal point. However, a high-powered laser is required for
two-photon microscopy, since the photon density at the focal point must be roughly one million
times that required for confocal microscopy.
2.6 INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY (ICP-MS)
FIGURE 2-7: Inductively coupled plasma-mass spectrometry (figure from [43]).
Inductively coupled plasma-mass spectrometry (ICP-MS), also referred to as elemental
analysis, is a sensitive method used to quantify trace levels of elements. Prior to injection into the
ICP-MS, solid and liquid samples are digested (i.e. solubilized and homogenized) using nitric
acid and an elevated temperature. The resulting aqueous samples are injected into the ICP-MS
(see FIGURE 2-7) via a peristaltic pump. Then, the sample is atomized and ionized in a high-
temperature argon plasma. Finally, the mass spectrum of the plasma is acquired.
Note that this method is time-consuming because all glassware and vials must be
meticulously cleaned (using a process which lasts several days) in order to minimize background
levels, allowing for the analysis of trace levels of elements in samples. The process of sample
digestion and preparation for injection also occurs over several days.
CHAPTER 3
EVALUATING THE SPLIT-THICKNESS SKIN MODEL FOR THE
US/SLS-ENHANCED TRANSDERMAL DELIVERY OF
HYDROPHILIC PERMEANTS
3.0 PREFACE
This study was originally motivated by unsuccessful attempts to quantify the delivery of
quantum dots through US/SLS-treated full-thickness skin (FTS). At the start of my thesis work, I
had aimed to utilize quantum dots as model permeants for studying the US/SLS-enhanced
delivery of nanoparticles. However, using the common quantum dot assaying methods of
UV/Vis absorption and spectrofluorimetry, I could not determine if the quantum dots were
delivered across the skin and into the receiver chamber of the Franz diffusion cell (see Chapter 2,
Section 2.1).
One possibility for not detecting quantum dots in the receiver solution was that the
quantum dots were not penetrating into the skin to begin with. To rule this out, I used confocal
fluorescence microscopy and two-photon fluorescence microscopy to show that quantum dots
were at least penetrating into the stratum corneum and diffusing into the epidermis. Since the
* Most of this chapter has been reproduced from JE Seto, BE Polat, RFV Lopez, D Blankschtein, and R Langer.
Effects of ultrasound and sodium lauryl sulfate on the transdermal delivery of hydrophilic permeants: comparative in
vitro studies with full-thickness and split-thickness pig and human skin. Journal of Controlled Release 145, 26-32
(2010).
stratum corneum is widely considered to be the major diffusion barrier to hydrophilic permeants,
the next logical step was to consider that the dermis was acting as a diffusion barrier to the
quantum dots. Next, preliminary experiments were conducted with US/SLS-treated split-
thickness skin (STS); STS is prepared by partially removing the dermis from FTS (see Chapter 2,
Section 2.3). In these preliminary studies, the use of STS skin led to a higher concentration of
quantum dots in the receiver chamber. This could be explained in two ways: (1) compared to
FTS, the STS has less dermis ("sink" material) in which steady-state diffusion must be
established before quantum dots pass into the receiver chamber, and/or (2) the US/SLS-enhanced
permeability of STS is higher than that of FTS. The use of STS to obtain higher concentrations
of quantum dots in the receiver chamber would only be justified if it was demonstrated that (2) is
not true. Therefore, it became necessary to show that STS and FTS are equivalent skin models
for US/SLS-enhanced transdermal permeability studies (i.e. their enhanced permeabilities are
comparable), as described in this chapter.
3.1 INTRODUCTION
The simultaneous application of low-frequency ultrasound and the surfactant sodium
lauryl sulfate (referred to as US/SLS) to skin enhances transdermal drug delivery in a synergistic
mechanical and chemical manner [19,21]. With the advance of US/SLS, as well as of other
transdermal drug delivery enhancement methods [44,45], it is now possible to transdermally
deliver therapeutic macromolecules (including proteins, vaccines, and drug delivery vehicles) in
significant amounts [46-48]. The delivery targets for these macromolecules are the Langerhans
cells in the epidermis or the blood capillaries just below the epidermis. In the case of
macromolecules, one must now consider the dermis as a potential artificial diffusion barrier in in
vitro transdermal drug delivery studies, regardless of the hydrophilicity of the macromolecule.
The dermis may act as a reservoir (i.e. a diffusion sink) for absorbed macromolecules due to
steric hindrance effects or interactions between the macromolecules and the dermal components
[7,49,50]. Therefore, split-thickness skin (STS) would be an attractive alternative skin model to
full-thickness skin (FTS) to reduce the barrier properties of the dermis and to more accurately
study the US/SLS-enhanced transdermal delivery of therapeutic macromolecules. Yet, all in vitro
US/SLS studies have been carried out using the well-established FTS model [51-57].
STS is typically prepared from full-thickness skin (FTS) using a dermatome, which
removes much of the dermis from FTS (see Chapter 2, Section 2.3). Even though STS is a
common skin model for in vitro transdermal drug delivery studies, it is not at all clear that STS is
a suitable skin model for the application of US/SLS.* This is because US/SLS enhances skin
permeability in a synergistic mechanical and chemical manner [19,21], and since FTS and STS
differ in the thickness of dermis acting as an underlying mechanical support, FTS and STS may
undergo different extents of skin structural perturbation in response to the US/SLS treatment. In
fact, the possibility that FTS and STS could respond differently to the application of US
motivated a previous comparative study on US-treated skin models [58] that was completed
before US was combined with SLS to more effectively enhance skin permeability [15,19,59].
Since the US/SLS treatment was found to be more effective than the previously used US
treatment [15,19,59], and since the US/SLS treatment is the currently used one in clinical
* Note that the alternative protocols involving applying US/SLS to FTS and then partially removing the dermis to
create STS are not practically feasible. This is mainly because the skin must be clamped into a diffusion cell during
the US/SLS treatment, resulting in a partially compressed skin sample from which the STS preparation is difficult.
For details, see Appendix, Section 3.5.
applications [35,60], a similar comparative study on US/SLS-treated FTS and STS is clearly
needed.
With the above need in mind, the primary objective was to investigate whether US/SLS-
treated STS would be a suitable alternative to the well-established US/SLS-treated FTS model.
This comparative study was performed on two pig skin models and three human skin models: pig
FTS (pFTS), 700-pm-thick pig STS (p700), human FTS (hFTS), 700-pm-thick human STS
(h700), and 250-pm-thick human STS (h250). Note that the third human skin model is the
thinnest that could be consistently prepared using a dermatome, and that pig STS models with
thicknesses ! 450 pm are not suitable for US/SLS treatment (see Appendix, Section 3.6). The
aqueous porous pathway model was utilized to compare the effects of US/SLS treatment on the
skin permeability and the effective skin aqueous pore radius of the hydrophilic transport
pathways within these five skin models. The following will be shown in this chapter: (1) pig FTS
and STS models exhibit similar US/SLS-enhanced permeabilities and pore radii after US/SLS
treatment, (2) human FTS and STS models exhibit different permeabilities and pore radii after
US/SLS treatment, and (3) a comparison of the US/SLS treatment times for the skin models
strongly suggests that intrinsic differences within pig and human skin are contributing to the
observed differences in (1) and (2). The strengths and weaknesses of each skin model
investigated will be discussed. In addition, two examples will be provided to compare pig STS to
FTS for in vitro US/SLS experiments in the case of gold nanoparticles and quantum dots, which
serve as well-characterized, model hydrophilic macromolecular permeants. Specifically, it will
be demonstrated that due to a thinner dermal layer, gold nanoparticles and quantum dots diffuse
through STS in greater amounts compared to FTS. These results suggest that the use of pig STS
over FTS may be beneficial in future in vitro studies on the US/SLS-enhanced transdermal
delivery of hydrophilic macromolecules.
3.2 MATERIALS AND METHODS
3.2.1 CHEMICALS
14C-labeled sucrose in sterile water (600 mCi/mmol) was obtained from American
Radiolabeled Chemicals (St. Louis, Missouri). Phosphate buffered saline (PBS) tablets and SLS
solution (20 w/v/o in water) were obtained from Sigma-Aldrich (St. Louis, Missouri). PBS was
prepared from PBS tablets according to the manufacturer's instructions. Hionic-Fluor
scintillation cocktail was obtained from PerkinElmer (Waltham, Massachusetts). Gold
nanoparticles, with a core diameter of 4.6 ± 1.5 nm (mean ± SD) and an 11-mercapto-1-
undecanesulphonate ligand shell, were a gift from Professor Francesco Stellacci's group at MIT
(synthesized using a published method [61]). Quantum dots with a CdSe core, ZnS shell,
amphiphilic polymer and polydiallyldimethylammonium chloride ligand coating, and 20-nm
hydrodynamic diameter (catalog no. QSQ-600) were obtained from Ocean NanoTech
(Springdale, Arkansas). Nitric acid (BDH, Aristar* Ultra grade), hydrochloric acid (BDH,
Aristar* Ultra grade), hydrogen peroxide (EMD Chemicals, Suprapur* grade), and certified gold,
cadmium, and indium stock standards (BDH, Aristar* grade) were obtained from VWR
International (West Chester, Pennsylvania). Deionized water dispensed from a Milli-Q academic
water purification system (Millipore, Bedford, Massachusetts) was used to prepare all solutions.
3.2.2 SKIN PREPARATION
Human FTS (21 - 50 year old Caucasian back and abdominal skin, excised 5 12 hours
post-mortem, shipped at -80*C) was obtained from National Disease Research Interchange
(Philadelphia, Pennsylvania) and stored at -80*C until use. Before each experiment, the skin was
thawed, the subcutaneous fat was removed with a razor blade, and excess hair was trimmed with
scissors. Female Yorkshire pig FTS (back and flank skin) was harvested within an hour after
sacrificing the 70-pound animal (purchased from E.M. Parsons & Sons, Hadley, Massachusetts).
The subcutaneous fat was removed, and the skin was sectioned into 1-inch strips before storing
at -80*C until use. Before each experiment, the skin was thawed and excess hair was trimmed
with scissors. After these preparations, the human and pig FTS thicknesses ranged from 2 to 4
mm and 1 to 2.5 mm, respectively. Then, STS was prepared from 1-inch strips of TS using an
electric dermatome (Zimmer Orthopaedic Surgical Products, Dover, Ohio). Next, the FTS or
STS strips were sectioned and placed on top of a 150-pm opening nylon mesh (Sefar Filtration,
Depew, New York) for support. High vacuum grease (Dow Coming, Midland, Michigan) was
applied to 15-mm inner diameter standard Franz diffusion cells (PermeGear, Hellertown,
Pennsylvania) in order to create a water-tight seal between the skin and the diffusion cell.
Finally, the skin was clamped into the diffusion cells. This experimental protocol was approved
by the Committee on Animal Care at MIT.
3.2.3 MEASUREMENT OF SKIN ELECTRICAL RESISTIVITY
The skin electrical resistivity, R, is a sensitive quantitative indicator of the structural state
of the skin [58,62,63]. R was measured according to a previously published method [53,58].
Briefly, a voltage was applied across the skin sample using two Ag/AgCl electrodes (#E242, In
Vivo Metric, Healdsburg, California). The skin electrical current was measured using a
multimeter, and the skin electrical resistance was obtained from the skin electrical current using
Ohm's Law (taking into account the background resistance). The skin electrical resistance was
multiplied by the skin area to obtain the value of R. This method was used to: (1) check the
initial structural state of the skin-any skin sample with an initial R value of < 50 kf cm2 was
considered damaged [64,65] and was discarded, (2) determine if the desired value of R had been
reached during US/SLS treatment, indicating that the desired extent of skin structural
perturbation was attained, and (3) determine the average value of R during the time period when
the skin permeability to sucrose was measured. The values measured in (3) were used in the
analysis described in Section 3.2.9.
3.2.4 US/SLS PRE-TREATMENT OF THE SKIN
The protocol consisted of first pre-treating skin with US/SLS, and then carrying out a
passive sucrose permeation experiment for 26 hours to measure the US/SLS-enhanced steady-
state skin permeability to sucrose. For the first step of the protocol, US/SLS was applied to the
intact skin samples based on a previously published method [52], with the following
modifications: US, with the probe tip immersed in a coupling medium containing 1 w/v% SLS in
PBS, was applied to the skin samples with a VCX 500 and a coupler probe (Sonics & Materials,
Newtown, Connecticut) at the following typical US parameters [28]: frequency - 20 kHz,
intensity - 7.5 W/cm2, pulse length - 5 seconds on, 5 seconds off, and distance between the probe
tip and the skin - 3 mm. The US intensity was calibrated using calorimetry [31]. The US/SLS
treatment was stopped at least every 2 minutes to determine if the desired R value was attained
and to replace the coupling medium (to minimize thermal effects [21]). The aim of the US/SLS
treatment was to attain a range of R values, corresponding to a range in the extent of skin
structural perturbation. The maximum and minimum R values attained were 40 kQ cm 2
(corresponding to a minimal amount of US/SLS treatment) and 0.4 kSQ cm2 (within the range of
R values attained using an FDA-approved ultrasonic skin permeation device in clinical
applications [37,60]), respectively.
3.2.5 MEASUREMENT OF SKIN PERMEABILITY TO SUCROSE
After applying US/SLS treatment to skin (see Section 3.2.4), the skin permeability to
sucrose was measured. Sucrose was previously determined to be a reliable hydrophilic probe
molecule for using the porous pathway model to estimate the skin aqueous pore radius [66].
US/SLS-treated skin samples were remounted into clean, dry Franz diffusion cells. 12 mL of
PBS was added to the receiver chambers, and 2 mL of donor solution containing 14C-labeled
sucrose in PBS was added to the donor chambers. Typical donor solution concentrations ranged
from 5 pCi/mL for the skin samples with R values of 40 k.i cm2 to 0.3 gCi/mL for the skin
samples with R values of 0.4 k2 cm2 . Note that the donor solution concentrations were chosen
such that the amount of 14C in the receiver solution aliquots was at least ten times that in PBS
(background). Diffusion experiments were conducted at room temperature (25*C) and under
occluded conditions by sealing the donor chambers and sampling ports with parafilm. The
receiver solutions were magnetically stirred at 400 RPM.
Samples were withdrawn from the diffusion cells during the steady-state domain at five
predetermined time points from 18 to 26 hours (the attainment of steady-state diffusion is
discussed in the Appendix, Section 3.7). At each time point, R was measured, 200-pL aliquots of
the donor solutions were withdrawn, and 400-pL aliquots of the receiver solutions were
withdrawn. Each receiver solution aliquot was immediately replaced with an equal volume of
PBS. After mixing each aliquot with 5 mL of scintillation cocktail, the radioactivity of the
aliquots was measured using a Tri-Carb 2810TR liquid scintillation analyzer (PerkinElmer,
Waltham, Massachusetts). Finally, the skin permeability to sucrose, P, was calculated at steady-
state, sink conditions using the following well-known equation:
P= ACdAt (3-1)
where Vis the volume of PBS in the receiver chamber, A (= 1.77 cm2) is the permeation area, Cd
is the average sucrose concentration in the donor chamber, and (AC/At) is the steady-state rate of
change in sucrose concentration in the receiver chamber (taking into account the replacement of
the receiver aliquots and the background radioactivity) [28]. The experimental conditions for
which Eq. (3-1) is valid are discussed in the Appendix, Section 3.7.
3.2.6 CALCULATION OF THE EFFECTIVE SKIN AQUEOUS PORE RADIUS
The main assumption of the aqueous porous pathway model is that a hydrophilic
permeant traverses the skin via the same aqueous porous pathway as the conducting ions in the
electrolyte solution surrounding the skin (in PBS, the dominant ions are Na* and Cl-) [66]. The
porous pathway model was developed in order to quantify the effects of steric hindrance
resulting from the radii of the permeant and of the conducting ions relative to the effective skin
aqueous pore radius, por, [66]. Accordingly, rp,,e can be determined by comparing the hindered
transdermal diffusion of the permeant (related to P) to that of the conducting ions (related to R)
[66].
Based on the porous pathway model [66], the relationship between P and R is given by:*
log P= log C- log R (3-2)
where C is defined as follows [66]:
kT DH(2 A,)
C= (3-3)2z2Fc,,,,eO Dio,,H (4A,,)
where k is the Boltzmann constant, T is the absolute temperature, z is the electrolyte valence, F is
the Faraday constant, ci,,n is the electrolyte molar concentration, eo is the electronic charge, D," is
the diffusion coefficient of solute i (permeant (p) and ion) at infinite dilution, H(i) is the
diffusive hindrance factor of solute i, and A; is the ratio of the radius of solute i, ri, and rpore (that
is, Ai = rilrpore). In previous applications of the porous pathway model [33,52,53,58,66-69], H(i)
was evaluated using the Renkin equation for Ai < 0.4 as follows:
HI (,=1 )212.104A, +2.093' - 0. 9515] (3-4)
The hydrodynamic theory of hindered transport has advanced since the Renkin equation
was first introduced in 1954. A more accurate expression for HLi) was developed in 2006.
Specifically, for ti 5 0.95, H(L.i) is given by [70]:
9H(4)=1+-AIn, -1.56034A +0.5281554 2+1.915211/
8 (3-5)
-2.81903A +0.270788 5 +1.10115A6 -0.435933A! 7
Note that C in Eq. (3-3) is a function of a single skin structural parameter, rpore (through A1
The logarithmic form is used so that the regressed slopes and intercepts (see Section 3.2.9) are of the same order of
magnitude.
= r/irpore in H(p)/H(.lion)), as well as of other parameters that are not intrinsic to the skin
structure. Furthermore, by evaluating Eq. (3-3) for various values of rpore, one finds that log C
increases (i.e. becomes less negative) as rpore increases.
For a log P - log R data set, each data point was extrapolated to the y-axis using a
theoretical slope value of -1 (see Eq. (3-2)) to calculate log C. From the extrapolated log C
values, the average log C value and associated 95% confidence interval were calculated. Finally,
rpore was determined from the average log C value using Eq. (3-3), Eq. (3-5), and the following
parameter values: k = 1.38066-10-23 J/K, T 298 K, F = 9.6485-104 C/mol, eo = 1.6-10-'9 C, z =
I (for NaCl, the dominant electrolyte), ci,. = 0.137 M, D,,", = 1.33-10-' cm2/s at 298 K, ri = 2.2
A, D,"= 5.20-10-6 cm2/s at 298 K, and r= 5.55 A. The endpoints of the 95% confidence interval
for rpore were calculated using the endpoints of the 95% confidence interval for log C.
3.2.7 US/SLS-ENHANCED TRANSDERMAL DELIVERY OF GOLD NANOPARTICLES
3.2.7.1 TRANSDERMAL DELIVERY OF GOLD NANOPARTICLES
Pig FTS and STS samples were pre-treated with US/SLS (as described in Section 3.2.4)
to attain R values of 0.8 - 1.2 kW cm 2. Then, the US/SLS-treated skin samples were remounted
into clean, dry Franz diffusion cells. 12 mL of PBS was added to the receiver chambers, and 0.3
mL of the donor solution (0.1 w/v% gold nanoparticles in water) was added to the donor
chambers. Diffusion experiments were conducted for 24 hours at room temperature (25*C), and
the receiver solutions were magnetically stirred at 400 RPM.
At the end of each diffusion experiment, the receiver solution and the skin sample were
collected. To minimize interference with the ICP-MS analysis of trace metals (see Section
3.2.7.2), the PBS salts were dialyzed out of the receiver chamber solution using a SnakeSkin
3500 molecular weight cut-off regenerated cellulose membrane (Pierce Biotechnology,
Rockford, Illinois) that was placed in a stirred beaker of deionized water. The beaker was
recharged with fresh water three times over a period of 24 hours. From the skin sample, the skin
area exposed to US/SLS pre-treatment and passive gold nanoparticle diffusion was isolated using
scissors; then, the epidermis was mechanically separated from the dermis using a spatula [71].
Finally, the dialyzed receiver solution and the dermis were analyzed by ICP-MS as described in
Section 3.2.7.2.
3.2.7.2 QUANTIFICATION OF GOLD NANOPARTICLES BY ICP-MS
Inductively coupled plasma-mass spectrometry (ICP-MS) was performed using a
PlasmaQuad 2+ Quadrupole Mass Spectrometer (Fisons Instruments, Merrimac, Massachusetts)
to quantify the amount of gold in various samples, based on a previously published method [72].
Briefly, the receiver solutions and dermis samples (see Section 3.2.7.1) were digested under
reflux by the addition of aqua regia in polyfluor alkoxy vials (Savillex, Minnetonka, Minnesota)
for 16 hours at 110 - 1200C. Each acid digestion sample was then diluted using 1% nitric acid.
To ensure the accuracy and precision of the technique, each sample was spiked with a standard
indium ("In) salt solution prior to injection into the ICP-MS system. Calibration plots were
generated using gold standard solutions.
3.2.8 US/SLS-ENHANCED TRANSDERMAL DELIVERY OF QUANTUM DOTS
3.2.8.1 TRANSDERMAL DELIVERY OF QUANTUM DOTS
Quantum dots were supplied as a 2 pM solution containing unbound polydiallyldimethyl
ammonium chloride ligands. The unbound ligands were removed using the following supplier-
recommended procedure: the quantum dot solution was dialyzed using Spectra/Por 100,000
molecular weight cut-off cellulose ester membranes (Spectrum Laboratories, Rancho
Dominguez, California) that were placed in stirred beakers of deionized water. The beakers were
recharged with fresh water three times over a period of 24 hours. The dialyzed quantum dot
solution had a final concentration of 0.62 t 0.06 pM, which was used as the donor solution in
transdermal diffusion experiments as described in Section 3.2.7.1 (the R values attained were
1.3 -2.3 kW cm2)
3.2.8.2 QUANTIFICATION OF QUANTUM DOTS BY ICP-MS
The quantification of 'Cd (cadmium, an element of the quantum dot core) by ICP-MS
was conducted as described in Section 3.2.7.2, with the following modifications: (1) samples
were digested under reflux by the addition of nitric acid and hydrogen peroxide, and (2) acid
digestion samples were then dried at 60*C before redissolution in 1% nitric acid. Since the
quantum dot donor solution concentration was low, experiments without quantum dots were also
conducted for measuring background cadmium amounts to determine whether the cadmium
amounts in the receiver solution were significantly greater than background amounts. Calibration
plots were generated using cadmium standard solutions.
3.2.9 STATISTICAL ANALYSIS
A linear regression was fitted to the log P - log R data set for each skin model
considered. The regression parameters were subjected to an analysis-of-variance and an analysis-
of-covariance [73] as discussed in Sections 3.3.1 and 3.3.2. Two-sample, two-tailed t-tests
assuming unequal variances were used to compare log C values, US/SLS treatment times, gold
amounts, and cadmium amounts. In all analyses, p values < 0.05 were considered to be
statistically significant.
Note that a matter of significant importance was that t-tests which assume unequal
variances were used to compare log C values. Previous analyses based on t-tests assuming equal
variances resulted in erroneous conclusions.
3.3 RESULTS AND DISCUSSION
3.3.1 LOG P - LOG R CORRELATIONS ARE WELL-DESCRIBED BY THE POROUS
PATHWAY MODEL
FIGURE 3-1 shows the experimental log P - log R correlations obtained for the five skin
models investigated, and TABLE 3-1 lists the log P - log R linear regression parameters. TABLE
3-1 shows that the regressed slopes for all five skin models are not significantly different from
-1. In addition, the r2 values of the regressions are within the expected range reported in the
literature [66,74], and an analysis-of-variance showed that the regressions are statistically
significant (the linear regressions "fit" the data, or the observed variations in P are explained by
the linear log P - log R correlations).
Since the regressed slopes are -1 and the linear regressions are statistically significant,
two conclusions can be drawn. First, within the range of US/SLS treatment conditions examined,
the five skin models considered respond to US/SLS in a predictable manner. Specifically, the
transdermal transport of sucrose through the five US/SLS-treated skin models is well-described
by the porous pathway model. Therefore, the porous pathway model can be applied to compare
the structural parameters of the hydrophilic transport pathways within each of the five skin
models, which is discussed in Section 3.3.2.
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FIGURE 3-1: Comparison of the experimental log P - log R correlations: (A) hFTS, n = 36, (B) h700, n = 44, (C) h250, n = 34, (D)
pFTS, n = 47, and (E) p700, n = 35. Each data point represents one experiment. The solid lines represent the linear regressions fitted to
each data set. The statistical parameters associated with the linear regressions are listed in TABLE 3-1.
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TABLE 3-1: Statistics for the log P - log R data set for each skin model.
Linear Regression ParametersSkin TypeloCae
Slope ab Intercept a lCa
hFTS -1.08 0.10 -2.99 0.09 0.93 -3.05 ± 0.14
h700 -1.04 0.23 -2.88 0.20 0.66 -2.91 ± 0.36
h250 -1.09 0.27 -2.63 0.20 0.68 -2.69 ± 0.31
pFTS -1.07 ± 0.08 -2.90 t 0.07 0.94 -2.95 ± 0.16
p700 -1.07 0.23 -2.85 0.16 0.74 -2.89 ± 0.27
a Range corresponds to the 95% confidence interval.
b Slopes are not significantly different from -1.
* The average intercept value, log C, was obtained by extrapolating each data point to the y-axis
using a slope of -1 (see Section 3.2.6). Log C is equivalent to the regressed intercept when the
regressed slope is exactly -1.
Second, within each skin model investigated, rpore does not vary significantly over the
range of R values attained using US/SLS treatment.* In previous studies where US/SLS was
applied to pFTS [33] and hFTS [52] to attain a range of R values, the results indicated that rpore
did not vary significantly with R (i.e. rpore determined from mannitol delivery did not vary
significantly with US/SLS dose). In this respect, the findings for the STS models investigated
compare well with the findings for the well-established FTS models investigated and with the
previous results reported in the literature for pFTS [33] and hFTS [52].
3.3.2 COMPARISON OF LOG P - LOG R CORRELATIONS AMONG SKIN MODELS
To compare the extent of structural perturbation within each US/SLS-treated human skin
model, a statistical analysis was carried out to compare the regressed slopes and intercepts. For
hFTS, h700, and h250, an analysis-of-covariance showed that there is no significant difference
among the slopes of the three regression lines, but that the intercepts are significantly different.
Pairwise t-tests further showed that the log C values for these three human skin models are
significantly different. Recall that log C increases as rpre increases (see Section 3.2.6).
Physically, these results indicate that of the three human skin models, h250 undergoes the largest
extent of structural perturbation (resulting in the largest rpore value; see TABLE 3-2), while hFTS
undergoes the smallest. These results strongly suggest that dermal thickness is significant during
* Recall that changes in rpor, affect the extrapolated intercept value from each data point (see Section 3.2.6). If r,,,
varied significantly with the extent of skin structural perturbation induced by the US/SLS treatment, then the
extrapolated intercepts would vary, and therefore, the regressed slope would be significantly different from -1 and/or
the log P - log R correlation would be nonlinear. On the contrary, in Section 3.3.1, it was determined that the
regressed slopes are -1 and that the linear regressions are statistically significant. Therefore, this indicate that within
each skin model investigated, rre does not vary significantly over the range of R values attained using US/SLS
treatment.
the in vitro US/SLS application to human skin.* Therefore, while all three human skin models
investigated react to US/SLS in a manner that is well described by the porous pathway model,
the three human skin models considered are not interchangeable.
Turning next to pFTS and p700, the statistical analysis described above showed that
neither the slopes nor the intercepts of the two regressions are significantly different; therefore,
the regression lines coincide. Subsequently, a t-test showed that there is no significant difference
among the log C values (see TABLE 3-1) for pFTS and p700. This result implies that there is no
significant difference among the rpore values. Based on the results of the statistical comparison of
the regressed slopes, regressed intercepts, and log C values for pFTS and p700, there is no
significant difference between the structures of the hydrophilic transport pathways within these
two pig skin models, which are therefore comparable. This indicates that the hydrophilic
transport pathways within pFTS and p700 undergo similar extents of structural perturbation in
response to the US/SLS treatment. This is an important finding that suggests that p700 may be
utilized as an alternative skin model for in vitro studies of the US/SLS-enhanced transdermal
delivery of hydrophilic permeants. The results further indicate that dermal thickness is not as
significant during the in vitro US/SLS application to pig skin compared to human skin.
* The dermal thickness is not significant during the passive sucrose permeability experiments. The larger pore sizes
observed in h700 and h250 cannot be attributed to the reduction of dermis in the passive permeability experiments,
since the pores of the dermis are considered to be infinitely large in relation to sucrose. A reduction in the dermal
layer with infinitely-large pores would logically result in a reduction in the skin model's effective aqueous pore size.
On the contrary, the pore sizes of US/SLS-treated h700 and h250 were determined to be greater than that of hFTS
(see Table 3-2). Therefore, one can conclude that the reduction in the dermis must play a more important role during
the US/SLS pre-treatment phase than during the passive permeability experiments.
TABLE 3-2: Average values of the pore radii measured using sucrose as the probe permeant.
Skin Type rpore (A) a,b
Low Average High
pFTS+p700* 26 113 >120
hFTS 23 39 >120
h700 19 >120 >120
h250 55 >120 >120
a The low and high values correspond to the endpoints of the 95% confidence interval for rpo,.
b With sucrose as the probe permeant, the rpore value of oo is obtained when log C > -2.86. The
physical significance of this value is that rpore is significantly larger than the radius of sucrose
(5.55 A), such that the diffusion of sucrose through the aqueous pores is not sterically hindered.
This limiting case has previously been studied by measuring the transdermal transport of small
hydrophilic permeants through dermis, where the rpr, value is considered to be oo in relation to
the size of the probe permeant since the dermis has a macroscopic porous structure [52,66].
Based on these studies (which utilized Eq. (3-4)), due to experimental error in determining the
value of log C, the porous pathway model did not distinguish between rpore values of 100 A and
co when used to quantify the transdermal diffusion of small hydrophilic permeants such as
mannitol and sucrose [52,66]. Based on Eq. (3-5), which is more accurate than Eq. (3-4), the
limit on rpor becomes 120 A. Note that permeants larger than sucrose will experience greater
steric hindrance within the aqueous pores. Therefore, pore radii >120 A may be measured using
larger probe permeants.
* As discussed in Section 3.3.2, there is no significant difference among the log C values for the
pig skin models investigated. Therefore, an rp,,r value can be calculated from the combined log P
- log R data set for the two pig skin models [73].
Interestingly, the observed difference in the results for the pig and human skin models is
reflected in the US/SLS treatment times for the skin models (see TABLE 3-3). The treatment
times for pFTS and p700 are not significantly different, while the treatment times for the human
skin models vary with skin thickness. Notably, there is a significant difference between the
US/SLS treatment times for h700 and p700, which strongly suggests that intrinsic differences
within pig and human skin (e.g. differences in dermal elastic fiber content [75]) are contributing
to the differences in the results for pig and human skin. It is important to note that although pig
and human skin are similar, they also display significant differences, as outlined in [75].
In comparing the r2 values for the five skin models, note that those associated with STS
are smaller than those associated with FTS (see TABLE 3-1). This difference is attributed to the
greater variability in tension that one can experimentally impart onto STS (since it is thinner than
FTS) when mounting skin into a diffusion cell. It has previously been proposed that skin
permeability is affected by lateral strain in the skin [76]. Furthermore, the elasticity of a
biomaterial (such as skin) is an important property that affects ultrasonic cavitation bubble
dynamics and microjet formation in the fluid surrounding the biomaterial [77]. Therefore,
variability in skin tension likely translates into variability in the mechanism of action of US/SLS
on the skin, including more variability in the STS data. Additional experiments would be needed
in order to test this hypothesis. In future studies, one should be cognizant of skin tension when
mounting skin into a diffusion cell. The development of a procedure to mount STS into a
diffusion cell with consistent skin tension may reduce the observed variability in the STS data.
TABLE 3-3: Net US/SLS treatment times for samples treated to attain R values of 1.5 ± 0.6
kQ cm2. a
Skin Type n Time (min) b
hFTS 8 10.6 8.8
h700 10 5.1 2.6
h250 6 2.8 ± 2.8
pFTS 14 2.5 ± 0.7
p700 10 2.9± 1.7
a The treatment times are reported for a small subset of the range of R values investigated
(compared to the range investigated that spanned two orders-of-magnitude) in order to make
useful statistical comparisons among the treatment times for the skin models. This range of R
values was attained in an in vivo clinical study (reported in ref. [60] as mean ± SD). Up to 45
seconds of US/SLS treatment time was required to attain this range of R values in the clinical
study [60]. However, it is important to note that the clinical ultrasonic skin permeation device
was operated at a frequency of 55 kHz. It has previously been shown that the treatment time
required to obtain a desired R value varies with US frequency [33,78]. However, by varying US
frequency and US/SLS treatment time until different skin samples reach the same skin electrical
resistivity value, the skin barriers are permeabilized to similar extents [33,58,78].
b Range corresponds to mean ± SD for n samples.
3.3.3 US/SLS-ENHANCED DELIVERY OF GOLD NANOPARTICLES IS GREATER
THROUGH P700 THAN THROUGH PFTS
The findings reported in Section 3.3.2 suggest that p700 can be considered to be an
alternative skin model to pFTS. To illustrate why STS may be preferred over FTS in in vitro
experiments in the case of macromolecules, gold nanoparticles were used as well-characterized,
model hydrophilic macromolecular permeants to compare their US/SLS-enhanced transdermal
delivery through pFTS and p700. In in vitro transdermal delivery experiments, hydrophilic
molecules that permeate through the skin are ordinarily quantified in the receiver solution [79]
because the dermis is not considered a significant barrier for these drugs. However, as proposed
in this work, the dermis can also act as a barrier to hydrophilic macromolecules. Accordingly, the
gold, present in the core of the gold nanoparticles studied, was analyzed both in the receiver
solution and in the dermis.
Between pFTS and p700, there was no significant difference in the total amount of gold
found in the dermis and the receiver solution (see FIGURE 3-2A), which indicates that the total
amounts of gold nanoparticles penetrating past the epidermis (the major diffusion barrier to
hydrophilic permeants) over 24 hours are similar. This finding is consistent with the conclusion
that pFTS and p700 undergo similar extents of structural perturbation in response to the US/SLS
treatment (see Section 3.3.2). Interestingly, the fraction of gold nanoparticles penetrating past the
epidermis but remaining in the dermis after 24 hours was significantly larger when pFTS was
used (see FIGURE 3-2B). This suggests that the thicker dermis in pFTS acts as a greater
transdermal diffusion barrier to the gold nanoparticles, even though the gold nanoparticles are
hydrophilic. It is speculated that the dermis may act as a reservoir (i.e. a diffusion sink) for
absorbed macromolecules due to steric hindrance effects or interactions between the
macromolecules and the dermal components [7,49,50], or that there may be a longer lag time for
macromolecular diffusion through the thicker FTS dermis (which would support the hypothesis
that the dermis acts as an artificial barrier to hydrophilic macromolecules).
3.3.4 US/SLS-ENHANCED DELIVERY OF QUANTUM DOTS Is GREATER THROUGH
P700 THAN THROUGH PFTS
The experiments described in Section 3.3.3 were repeated using quantum dots as a
second hydrophilic macromolecular permeant, and similar results were obtained. Between pFTS
and p700, there was no significant difference in the total amount of cadmium found in the dermis
and the receiver solution (see FIGURE 3-3A), which indicates that the total amounts of quantum
dots clearing the epidermis (the major diffusion barrier to hydrophilic permeants) over 24 hours
are similar. This finding is consistent with the conclusion that pFTS and p700 undergo similar
extents of structural perturbation in response to the US/SLS treatment (see Section 3.3.2) and
with the findings for gold nanoparticles in Section 3.3.3. The fraction of quantum dots clearing
the epidermis but remaining in the dermis was slightly (but not significantly) larger when pFTS
was used (see FIGuRE 3-3B). This result is similar to the findings for gold nanoparticles, but the
variability in the pFTS data (likely resulting from variability in the dermal thickness) was too
great to detect a difference between pFTS and p700 at the 95% confidence level (p = 0.077 >
0.05). However, the amount of quantum dots reaching the receiver solution was still significantly
greater in p700 than in pFTS (see FIGURE 3-3C), which is consistent with the findings for gold
nanoparticles (see FIGURE 3-2C).
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FIGuRE 3-2: Quantification of gold (Au) in the dermis and in the receiver solution after 24 hours
of gold nanoparticle diffusion through US/SLS-treated pFTS and p700. (A) Total amount of gold
found in the dermis and receiver solution, indicating the total amount of gold nanoparticles
penetrating past the epidermis. (B) Fraction of gold nanoparticles penetrating past the epidermis
but remaining in the dermis. (C) Amount of gold found in the receiver solution. The amounts
found in pFTS and p700 are not significantly different in (A) but are significantly different in (B)
and (C). Data shown are the mean ± SD of n replicates; n = 4 for pFTS, n = 5 for p700.
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FIGuRE 3-3: Quantification of cadmium (Cd) in the dermis and in the receiver solution after 24
hours of quantum dot (QD) diffusion through US/SLS-treated pFTS and p700. (A) Total amount
of cadmium found in the dermis and receiver solution, indicating the amount of quantum dots
penetrating past the epidermis. (B) Fraction of quantum dots penetrating past the epidermis but
remaining in the dermis. (C) Amount of cadmium found in the receiver solution. The quantum
dot amounts found in pFTS and p700 are not significantly different in (A) and (B) but are
significantly different in (C). In (C), the background and quantum dot cadmium amounts
measured using pFTS are not significantly different. Data shown are the mean = SD of n
replicates; n = 6 for quantum dots, n = 3 - 7 for background.
3.3.5 STRENGTHS AND WEAKNESSES OF THE SKIN MODELS INVESTIGATED
This section discusses the strengths and weaknesses of the skin models investigated.
Excised human skin is considered the "gold standard" for in vitro transdermal studies. However,
it is difficult to obtain regularly. Pig skin is a common animal skin model used in in vitro
transdermal studies, particularly in US/SLS studies [28]. Excised pig skin is easier and cheaper
to obtain than excised human skin, and the US/SLS treatment time for pig skin is shorter than
that for human skin (see TABLE 3-3). Based on this comparison, pig skin is preferred over human
skin.
Next, FTS and STS are compared. In the general transdermal field, STS is typically
favored over FTS [80]. However, all previous in vitro US/SLS studies have been carried out with
FTS [51-57], probably because STS had not been evaluated as a suitable in vitro skin model for
US/SLS studies. One weakness of FTS is that its thickness varies with the location of skin
procurement and the method used to remove the subcutaneous fat. The thickness of STS is much
more uniform than that of FTS. However, there is more variability in the permeability data of
US/SLS-treated STS (see the r2 values in TABLE 3-1) compared to that of FTS. As discussed in
Section 3.3.2, this variability may be minimized by mounting STS into a diffusion cell with
consistent skin tension. If the variability cannot be adequately minimized, then one may need a
larger number of replicates in a study using STS.
The choice of using STS or FTS depends on the final purpose of the study and on the
permeant quantification methods available, including whether dermis solubilization is required to
determine the amount of delivered permeant. It is generally easier to quantify the amount of
permeant in the receiver solution than in the dermis because the sample collection is simpler and
no tissue solubilization or extraction is required. If dermis solubilization is not required, then the
diffusion cell can be sampled at more than one time point, and the skin permeability (as defined
in Eq. (3-1)) and absorption kinetics can be measured. Therefore, in spite of greater variability in
the STS permeability data, one may choose to use STS to: (1) obtain a larger amount of delivered
permeant into the receiver chamber solution for easier quantification (as shown in FIGuRE 3-2C
and FIGURE 3-3C), or (2) reduce the permeant donor concentration in order to obtain the same
amount of permeant in the receiver solution that one would obtain using FTS, thereby reducing
the amount and cost of material required for a study. On the other hand, if the amount of
permeant in the receiver solution is below the limit of quantification for a desired method, then
permeant quantification in the dermis using tissue solubilization may be required. In this case, it
is beneficial to use p700 over pFTS because the dermis thickness is less variable (note that in
FIGURE 3-3, the quantum dot amounts in p700 were less variable than in pFTS). The above
issues are particularly important in the case of hydrophilic macromolecules, which pass through
skin in low amounts and may not attain steady state transdermal diffusion within 24 hours.
3.4 CONCLUSIONS
The log P - log R correlations between pig and human FTS and STS were compared in
the context of the aqueous porous pathway model, which was utilized to characterize the extent
of structural perturbation of the hydrophilic transdermal transport pathways in response to
US/SLS treatment. For the US/SLS conditions and the range of R values considered, US/SLS
enhances P in each skin model in a predictable manner that is well-described by the porous
pathway model. The key result of the investigation is that pFTS and p700 respond similarly to
US/SLS treatment, while hFTS, h700, and h250 respond differently to US/SLS. The significant
difference in US/SLS treatment times for p700 and h700 strongly suggests that the difference in
the results for pig and human skin is due to intrinsic differences within pig and human skin. In
comparing FTS and STS, it was shown that STS permeability data may be more variable, but the
thicker dermis in FTS acts as a greater transdermal diffusion barrier to macromolecules
(demonstrated using gold nanoparticles and quantum dots as model hydrophilic macromolecular
permeants; this result is graphically depicted in FIGURE 3-4). Because the dermis acts as an
artificial diffusion barrier, and pig skin is more readily obtained and responds faster to the
US/SLS treatment compared to human skin, the findings strongly suggest the use of p700 for
future in vitro studies on the US/SLS-enhanced transdermal delivery of hydrophilic permeants
(particularly, hydrophilic macromolecules).
Based on the results presented in this chapter, the original goal of investigating the
transdermal delivery of quantum dots (see Section 3.0) was pursued, using pig STS. In the next
chapter, then, the US/SLS-enhanced delivery of quantum dots was investigated using
complementary qualitative and quantitative methods (confocal fluorescence microscopy and
elemental analysis, respectively). In addition to the advantages of using STS described in Section
3.3.5, the use of STS in Chapter 4 provided additional benefits. Because STS has minimal
variation in dermal thickness, the use of STS reduced the variability in: (i) the amount of
quantum dots quantified in the dermis by elemental analysis (see Section 4.2.6.1), and (ii) the
compression of the skin when it is mounted into an imaging chamber for confocal microscopy
analysis (see Section 4.2.6.2), which affects the observed quantum dot penetration depth.
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FIGURE 3-4: Graphical depiction of key results. (A) Pig FTS and STS respond similarly to the
US/SLS treatment. (B) Macromolecules (gold nanoparticles and quantum dots) clear the STS
dermis and reach the receiver solution in greater amounts.
3.5 APPENDIX A: METHODS TO PREPARE US/SLS-TREATED SPLIT-THICKNESS
SKIN
Two methods may be utilized to prepare US/SLS-treated STS: (1) treat FTS with
US/SLS, and then use a dermatome to obtain US/SLS-treated STS, or (2) dermatome untreated
FTS to obtain STS, and then treat the STS with US/SLS.
Method (1) would really be the ideal method for preparing skin so that studies such as the
one described in this chapter are not necessary to validate STS of various thicknesses for
US/SLS treatment. However, from a practical standpoint, Method (1) is inefficient and not
feasible. FIGURE 3-5 illustrates why Method (1) is not practicallyfeasible. Skin must be clamped
firmly into the Franz diffusion cell in order to ensure accurate measurements of R to meet initial
skin structural integrity requirements as described in Section 3.2.3. In addition, skin is clamped
firmly during the US/SLS treatment. Recall that the treatment times reported in TABLE 3-3 are
net US/SLS treatment times. Since US is applied in a pulsed mode with an on/off ratio of 1:1
(see Section 3.2.4), a sample treated with US/SLS for one net minute really spends two minutes
under the US horn. Furthermore, in order to minimize the temperature rise in the coupling
medium and to determine if the desired value of R has been reached, at least once every two
minutes of US/SLS treatment, it takes ~1 minute to replace the 1% SLS coupling medium with
PBS, measure R, and replace the PBS with 1% SLS coupling medium for the next US/SLS
treatment period. Therefore, the total time that a skin sample is firmly clamped into a diffusion
cell during US/SLS treatment can be as long as 1 hour, particularly for the hFTS samples. From
experience, the outer, greased, and partially compressed skin area does not recover from being
clamped in a diffusion cell after US/SLS treatment. Because of this, it would be very difficult to
dermatome an uneven skin surface after US/SLS treatment.
FIGURE 3-5: Skin, after being clamped in a diffusion cell for US/SLS treatment. The small,
unclamped area in the center would be difficult to dermatome.
Furthermore, assuming that one could dermatome just the unclamped surface of the skin
that is exposed to US/SLS treatment, then the resulting STS would need to be mounted into a
smaller diffusion cell for the subsequent passive permeation experiment. However, US/SLS
treatment enhances skin permeability in a heterogeneous manner, producing localized transport
regions (LTRs) of greatly enhanced permeability compared to the surrounding regions of
US/SLS-treated skin (see Chapter 1, Section 1.4.3). Typically, LTRs cluster in the center of the
exposed skin beneath the US probe [28,51,81]; therefore, mounting the resulting STS into a
smaller diffusion cell may artificially enhance the skin permeability. Until LTR formation is
transformed into a homogeneous phenomenon, this alternative protocol is not feasible.
Second, Method (1) is inefficient because it is difficult to preserve the structural integrity
of the skin while dermatoming. From experience, dermatoming compromises ~20% of the skin
(as quantified by comparing the percentage of FTS and STS samples that have an initial R value
> 50 kM cm2). In addition, dermatoming is a relatively quick step in the experimental protocol.
On the other hand, US/SLS treatment is a relatively time consuming step of the protocol, with
some samples taking up to 1 hour to treat as described above. Therefore, it would be more
efficient to dermatome skin and apply US/SLS treatment to the samples that are deemed
structurally intact, rather than to treat FTS with US/SLS followed by dermatoming, which would
structurally compromise ~20% of the US/SLS-treated samples.
For all of the above reasons, Method (2) is preferred over Method (1) because it would be
more efficient and practical to first dermatome FTS and then verify that the resulting STS is
structurally intact (see Section 3.2.3) before applying US/SLS treatment to the STS.
3.6 APPENDIX B: PIG STS WITH THICKNESSES < 450 pM ARE NOT SUITABLE FOR
US/SLS STUDIES
Pig skin was dermatomed to thicknesses of 300 - 400 pm, and the skin permeabilities to
sucrose (with and without US/SLS enhancement) were compared to that of 700-jm thick pig
STS. The resulting skin permeabilities to sucrose were significantly more variable and greater
than that of 700-pm thick STS (see FIGURE 3-6). Subsequently, pig STS of 450-pm thickness
was prepared, and the skin permeabilities to sucrose (with and without US/SLS enhancement)
were measured. The passive skin permeability to sucrose was similar to that of 700-pm STS (see
FIGURE 3-6). However, after treating 450-pm thick STS with US/SLS, the enhanced skin
permeability to sucrose was not reproducible and was significantly higher than that of 700-pm
STS (see FIGURE 3-6). This suggests that the pig skin membrane at this thickness is too fragile to
withstand the US/SLS treatment. It is likely that the mechanical action of US/SLS was forceful
enough to enlarge the hair shafts in the pig skin into macroscopic holes. Additional studies are
required to investigate intermediate thicknesses between 700 gm and 450 gm in order to
determine the threshold thickness for which pig STS is suitable for US/SLS studies.
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FIGURE 3-6: Evaluation of log P - log R correlations for pig STS with thicknesses 5 700 gm for
passive and US/SLS-enhanced diffusion experiments. Each data point represents one experiment.
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3.7 APPENDIX C: VALIDITY OF EQUATION (3-1) AT STEADY-STATE, SINK
CONDITIONS
Equation (3-1) is only valid under the following conditions: (a) steady-state diffusion is
attained before the sampling period (i.e. the concentration gradient across the skin is constant and
the rate of sucrose accumulation in the receiver chamber is constant), and (b) the donor solution
behaves as an infinite source (i.e. the donor concentration is constant and is significantly greater
than the receiver concentration). In each diffusion experiment, if significant experimental error
was evident, or if the experimental conditions required for Eq. (3-1) to be valid were not
maintained, the diffusion data were discarded.
Note that diffusion cells were sampled manually, and not with an autosampling system.
With manual sampling, there were many opportunities for experimental error to occur. In order
to ensure that significant experimental error did not occur, three conditions (denoted below as I,
II, and III) were used to evaluate the consistency of the data from each diffusion experiment
(note that conditions (II) and (III) refer to the linear regression that was used to calculate AC/At
from the five data points generated from the receiver solution aliquots; see Section 3.2.5): (I) For
each sampling time point, the difference in concentration between the donor and the receiver
solutions (Cd - Cr) was calculated. Then, the maximum relative change in (Cd - Cr) over the five
time points was calculated as 1 - ((Cd - Cr)m/(Cd - Cr)max). If this value was greater than 7.9%
(the basis for selecting this threshold is discussed below), then the data were discarded because
conditions (a) and (b) above were not maintained; (II) If the correlation coefficient (r2) of the
regression was less than 0.771 (this threshold value was calculated using an analysis-of-variance,
which requires that the slope of a linear regression computed from five data points be
significantly different from zero [82]), then the linear regression was not statistically significant.
Therefore, the data were discarded because condition (a) above was not maintained; and (III) If
the lower bound of the 95% confidence interval for the y-intercept of the regression was positive,
i.e. the entire 95% confidence interval was positive, then the data were discarded because this
corresponds to a non-zero 14C concentration in the receiver chamber at the start of the diffusion
experiment. The above conditions resulted in discarding data from 20% of the experiments. The
use of an autosampling system would likely improve the protocol by reducing the number of
opportunities for experimental error to occur.
Regarding condition (I), the 7.9% threshold value was chosen because it is one standard
deviation greater than the average value of 2.89 ± 4.99% (mean ± SD; this is the experimental
error in measuring the concentration difference across the skin at steady-state, sink conditions).
This experimental error was calculated using the data set from the diffusion experiments
conducted for this study. After applying conditions (II) and (III) to the dataset, there were 209
skin samples from which the threshold was calculated. Based on this threshold, 13 samples were
discarded. The data from the remaining 196 skin samples are reported in this chapter.
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CHAPTER 4
QUANTITATIVE AND QUALITATIVE METHODS FOR
EVALUATING THE TRANSDERMAL DELIVERY OF NANOPARTICLES *
4.1 INTRODUCTION
The evaluation of skin penetration of rigid nanoparticles (e.g. metallic and polymeric)
and soft nanoparticles (e.g. liposomes and transfersomes) has recently attracted significant
attention [50,83]. This chapter focuses on rigid nanoparticles. Rigid nanoparticles are being
investigated for: (i) designing transdermal drug carriers (e.g. [84,85]), (ii) elucidating their
mechanism of transdermal penetration (e.g. [86]), and (iii) evaluating their biocompatibility (e.g.
[87]). Compared to traditional topical formulation strategies, drug-loaded nanoparticles offer
advantages which include protection of unstable active agents against degradation and prolonged
release of active agents [83]. In addition, the physicochemical properties of the active agents are
masked, and the physicochemical properties of the nanoparticle carrier (e.g. size, surface charge,
hydrophilicity, and shape [88-90]) can be designed to enhance the transdermal delivery of the
active agent. Furthermore, the nanoparticle carrier can be targeted to deliver the drug to specific
skin components, such as dendritic cells [91].
* Most of this chapter has been reproduced from RFV Lopezt, JE Setot, D Blankschtein, and R Langer. Enhancing
the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl
sulfate. Biomaterials 32, 933-941 (2011). tco-first authors
While rigid nanoparticles have potential as transdermal drug carriers, the penetration of
nanoparticles into the skin is significantly inhibited by the skin's inherent barrier properties.
Many studies have qualitatively shown that skin penetration is primarily limited to the stratum
corneum, the outermost skin layer (e.g. [90,92,93]). The ability of nanoparticles to penetrate into
the dermis has been debated, based on visual observations made using confocal microscopy (e.g.
[88-90,92]). The conflicting reports suggest that nanoparticle penetration into the dermis may
occur in very small amounts (e.g. [89]), but this amount has not been quantified previously.
Clearly, the success of nanoparticles as transdermal drug carriers depends on the ability of the
carrier to penetrate the skin at sufficient depths and in sufficient quantities.
In order to improve nanoparticle skin penetration, one may consider several methods that
have been developed to enhance skin permeability [83]. One method, the simultaneous
application of low-frequency ultrasound and the surfactant sodium lauryl sulfate (referred to as
US/SLS), has received FDA approval as a skin treatment method for enhancing topical lidocaine
uptake [37]. US/SLS has also been used to enhance the transdermal delivery of therapeutic
macromolecules in vivo [46]. This chapter reports on the first investigation of the application of
US/SLS treatment to enhance the passive skin penetration of rigid nanoparticles.
There is significant evidence that the extent of nanoparticle skin penetration depends on
the surface charge of the nanoparticle (e.g. [88,90]). Therefore, this investigation compared the
penetration of cationic, neutral, and anionic nanoparticles into US/SLS-treated and untreated
skin. Quantum dots (QDs) are the nanoparticles selected for this study because: (i) QDs can be
coated with various ligands, and therefore, QDs of various surface charges can be obtained, and
(ii) their fluorescent properties allow for the visualization of their transdermal route of
penetration. More specifically, this investigation compared the following properties of 10- and
20-nm cationic, neutral, and anionic QDs: (a) the penetration of these QDs into US/SLS-treated
skin and untreated skin, and (b) the penetration pathway of these nanoparticles. Based on the
findings, conclusions are drawn regarding the potential of US/SLS as a method to enhance the
skin penetration of nanoparticle drug carriers.
4.2 MATERIALS AND METHODS
4.2.1 CHEMICALS
Phosphate buffered saline (PBS) tablets and SLS solution (20 w/v% in water) were
obtained from Sigma-Aldrich (St. Louis, Missouri). PBS was prepared from PBS tablets
according to the manufacturer's instructions. NaCl was obtained from Mallinckrodt (Paris,
Kentucky). 70% isopropanol wipes were obtained from VWR (West Chester, Pennsylvania).
Deionized water dispensed from a Milli-Q academic water purification system (Millipore,
Bedford, Massachusetts) was used to prepare solutions. The chemicals used for the ICP-MS
analysis (see Section 4.2.6.1) are provided in Chapter 3, Section 3.2.1.
4.2.2 QuANTUM DOTS (QDS)
Spherical, water soluble, CdSe/ZnS quantum dots with one of three different surface
groups were obtained from Ocean NanoTech (Springdale, Arkansas). The surface groups
include: (1) cationic polydiallyl dimethyl ammonium chloride, (2) anionic carboxylic acid, and
(3) neutral amine. The physicochemical properties of the four QDs studied, referred to hereafter
as QDs A - D, are listed in TABLE 4-1. QD hydrodynamic diameter and zeta potential
measurements were performed at 25*C using a ZetaSizer ZS90 (Malvern Instruments, Malvern,
Worcestershire, England). QD solutions were dialyzed (as described in Chapter 3, Section
3.2.8.1) and 0.2-im filtered prior to analysis. Size measurements were performed at count rates
of 100 - 130 kcps. Sizes were obtained from a volume-based particle size distribution. Zeta
potentials were measured at the physiologically relevant pHs of 5 and 6 [94]. For zeta potential
measurements at pH 6, QDs were dispersed in 10% PBS. For zeta potential measurements at pH
5, QDs were dispersed in 1% PBS, and NaCl was added such that the ionic strength of the
solution was equal to that of 10% PBS. Zeta potentials were calculated from electrophoretic
mobilities using the Smulochowski approximation.
TABLE 4-1: Physicochemical properties of the QDs.
Hydrodynamic Zeta potential Zeta potential
diameter (nm) b (mV) at pH 5 c (mV) at pH 6 c
9.9 g 0.8 -27.6 3.2 -27.0 1.7
21.0 0.6 -1.2 0.3 -2.5 3.2
21.8 1.2 27.6 0.8 26.9 1.3
21.4 2.0 36.9 1.1 30.0 ±1.6 d
Classification
Anionic
Neutral
Cationic
Cationic
a This is the largest anionic QD available from this vendor.
b Mean ± SD of 6 - 9 measurements.
C Mean ± SD of 3 - 6 measurements.
d QD D is more cationic than QD C (p < 0.05).
QD
A a
B
C
D
4.2.3 SKIN PREPARATION
The following methods have been described in detail in Chapter 3, Sections 3.2.2 and
3.2.3. Briefly, 700-pm thick pig split-thickness skin (STS) samples were prepared according to a
protocol which was approved by the Committee on Animal Care at MIT. Then, each skin sample
was mounted in a Franz diffusion cell (PermeGear, Hellertown, Pennsylvania) with a 15-mm
inner diameter. Any skin sample having an initial electrical resistivity of < 50 khQ cm2 was
considered damaged and was discarded.
Pig STS, which has minimal variation in dermal thickness, was used in order to minimize
variation in: (1) the amount of QDs quantified in the dermis by ICP-MS (see Section 4.2.6.1),
and (2) the compression of the skin (when it is mounted into an imaging chamber for confocal
microscopy analysis; see Section 4.2.6.2), which affects the observed QD penetration depth. In
addition, Chapter 3 showed that pig STS is a convenient skin model for investigating the in vitro
US/SLS-enhanced transdermal delivery of hydrophilic macromolecules, including one of the
QDs studied in this chapter (QD C).
4.2.4 US/SLS TREATMENT OF SKIN
US/SLS treatment was applied to some of the skin samples until the desired skin
electrical resistivity value of 1.25 ± 0.25 kfQ cm2 was attained,* using the method described in
Chapter 3, Section 3.2.4, which is summarized next: US, with the probe tip immersed in a
coupling medium containing 1 w/v% SLS in PBS, was applied to the skin samples with a VCX
500 and a coupler probe (Sonics & Materials, Newtown, Connecticut) at the following typical
US conditions [28]: frequency - 20 kHz, intensity - 7.5 W/cm2, pulse length - 5 seconds on, 5
* This range of skin electrical resistivity values was attained in a US/SLS clinical study [60].
seconds off, and distance between the probe tip and the skin - 3 mm. The US intensity was
calibrated using calorimetry. The US/SLS treatment was stopped at least every minute to
determine if the desired skin electrical resistivity value was attained, as well as to replace the
coupling medium with a fresh one (to minimize thermal effects).
4.2.5 TRANSDERMAL DELIVERY OF QDs
US/SLS-treated and untreated skin samples were mounted into clean, dry Franz diffusion
cells. 12 mL of PBS was added to the receiver chambers, and 0.25 mL of 1 pM QDs in water
was added to the donor chambers. Passive diffusion experiments were conducted for 24 hours at
room temperature (25*C) and under occluded conditions by sealing the donor chambers and
sampling ports with parafilm. The receiver solutions were magnetically stirred at 400 RPM.
Control experiments were also conducted with water in the donor chamber for: (1) measuring
background cadmium amounts (recall that cadmium is present in the core of the QDs) for ICP-
MS analysis (see Section 4.2.6.1), and (2) configuring confocal microscopy settings (see Section
4.2.6.2).
4.2.6 ANALYSIS OF QD SKIN PENETRATION
In in vitro transdermal delivery experiments, molecules that permeate the skin are
ordinarily quantified in the receiver solution [79]. However, it was shown in Chapter 3 that the
dermis acts as a significant diffusion barrier to QDs. Therefore, both the receiver solution and the
dermis were analyzed for the presence of QDs.
Immediately following the end of each diffusion experiment, the receiver solution and the
skin sample were collected. To prepare the receiver solution for ICP-MS analysis, the receiver
solution was dialyzed to reduce the amount of PBS salts (see Chapter 3, Section 3.2.7.1). Then,
the entire volume of the dialyzed receiver solution was analyzed by ICP-MS. From each skin
sample, the skin area that was exposed to US/SLS treatment and subsequent passive application
of QDs (1.77 cm2) was cleaned carefully with isopropanol and PBS and then isolated using
scissors. Then, the STS sample was either analyzed by confocal microscopy or further prepared
for analysis of QD penetration into the dermis. For the latter analysis, the epidermis was
mechanically separated from the dermis using a spatula [71]. Then, the exposed dermal surface
was cleaned with isopropanol and PBS in order to minimize potential contamination resulting
from inadvertently transferring QDs from the epidermis to the dermis. Finally, the isolated
dermis sample was analyzed by either ICP-MS or confocal microscopy as described next.
4.2.6.1 QUANTIFICATION OF QD PENETRATION BY ICP-MS
Inductively coupled plasma-mass spectrometry (ICP-MS) was performed using a
PlasmaQuad 2+ Quadrupole Mass Spectrometer (Fisons Instruments, Merrimac, Massachusetts)
to quantify the amount of 'Cd (cadmium, an element of the QD core) in the receiver solutions
and the dermis samples based on a previously published method [72]. The Cd amounts were
converted into QD concentrations using calibration plots for each QD studied. It was verified
that the skin did not interfere in the quantification of QDs by contacting STS with known
concentrations of QDs.
The quantification limit for each type of QD considered (see TABLE 4-1) was established
as follows: Background Cd amounts were determined using at least three controls (see Section
4.2.5) in each set of experiments. The maximum amount of Cd found in these controls was
doubled; this factor of 2 was chosen to reasonably distinguish between QD and background Cd
levels. Using this method, the following quantification limits were determined: (i) 0.007 pmol for
QD A, (ii) 0.0 19 pmol for QD B, (iii) 0.118 pmol for QD C, and (iv) 0.004 pmol for QD D. Note
that in order to obtain these quantification limits, (1) all glassware, stirbars, and polyfluor alkoxy
vials needed to be meticulously cleaned, and (2) in Section 4.2.5, the Ag/AgC1 electrodes were
not introduced into the receiver chamber of the diffusion cells in order to minimize the presence
of trace metals. Detailed ICP-MS protocols are provided in the Appendix, Section 4.6.
For each US/SLS-treated skin sample, the following two quantities were calculated: (1)
the total amount of QDs penetrating past the epidermis (the major transdermal diffusion barrier),
which corresponds to the sum of the amount of QDs quantified in the dermis and in the receiver
chamber, and (2) the fraction of QDs that penetrated past the epidermis and remained in the
dermis, which corresponds to the amount of QDs quantified in the dermis divided by (1).
4.2.6.2 VISUALIZATION OF QD PENETRATION BY CONFOCAL MICROSCOPY
Within 1 - 3 hours after the QD skin penetration experiments, STS samples and dermis
samples were examined using a LSM 510 confocal microscope, Plan-Neofluar 1Ox/0.3 objective,
and AIM 4.2 software (Carl Zeiss, Jena, Germany). Skin samples were inserted into a 0.5-mm
thick imaging chamber (Coverwell PCI-A-0.5, Grace Bio-Labs, Bend, Oregon) with PBS as the
mounting medium. The imaging chamber was sealed on both sides with a No. 1.5 glass
coverslip. Confocal images were obtained in the plane parallel to the sample surface (xy-mode),
and optical sections were made in the z-stack mode. All images are 900 pm x 900 pm. Skin
samples without QDs were used as negative controls for configuring the microscope settings.
The top surface of the STS samples or of the dermis samples was defined by the scanning
depth yielding the highest average fluorescence intensity [86]. After examining the top surface,
the samples were turned upside-down, and the underside of the dermis was also examined in
search of deep QD penetration into the dermis. As a visual aid, a mark on the coverslip was used
to identify the bottom surface of the dermis.
In all figures, a red color scheme is utilized to illustrate routes of QD penetration. In
addition, as indicated in the figure captions for FIGURE 4-2C, FIGURE 4-2D, FIGURE 4-4B, FIGURE
4-5B, and FIGURE 4-6, these images were processed using ImageJ software (National Institutes of
Health, Bethesda, Maryland) [95]. The brightness and contrast of the specified images was
adjusted first by using the 'Auto' feature in order to enhance the visibility of the regions of QD
penetration, and second by increasing the minimum displayed pixel value. These adjustments
were propagated to three control images to ensure that the control images remained black. For all
images, it is important to recognize that they serve to provide qualitative information regarding
routes of QD penetration.
4.2.7 STATISTICAL ANALYSIS
Two-sample, two-tailed t-tests assuming unequal variances were used to compare QD
amounts and zeta potentials. In all analyses, p values < 0.05 were considered to be statistically
significant.
4.3 RESULTS
4.3.1 QUANTIFICATION OF QD PENETRATION INTO UNTREATED SKIN
The QDs penetrated into the dermis of untreated skin (see TABLE 4-2, Dermis of
untreated skin), but QD permeation across the skin and into the receiver chamber of the Franz
diffusion cell setup was not quantifiable using ICP-MS (not shown). Among the four QDs, QD C
penetrated into the dermis in the largest amounts (0.078% of the applied dose), in spite of the
fact that it was not the most cationic QD. QD A penetrated the skin in the smallest amounts
(0.006%), in spite of the fact that it was the smallest QD.
4.3.2 QUANTIFICATION OF QD PENETRATION INTO US/SLS-TREATED SKIN
The US/SLS treatment significantly enhanced the penetration of the QDs past the
epidermis (see TABLE 4-2, Total) by 500 - 1300%. In most cases, QDs fully permeated US/SLS-
treated skin and reached the receiver chamber in quantifiable amounts (see TABLE 4-2, Receiver).
QD C penetrated the skin in the largest amounts, while QD A penetrated the skin in the smallest
amounts. For all four QDs, the fraction of QDs that penetrated past the epidermis and remained
in the dermis was high, ranging from 0.80 to 0.99 (see TABLE 4-2, Dermis/Total). Interestingly,
the two cationic QDs (C and D) exhibited very different behaviors once they penetrated past the
epidermis; out of the four QDs studied, QDs C and D exhibited the smallest and largest
fractional retentions in the dermis, respectively.
TABLE 4-2: Quantification of QD skin penetration after 24 hours of diffusion. Data shown are the
mean ± SD of n replicates; n = 5 - 6 for US/SLS-treated skin, n = 3 - 5 for untreated skin.
Dermis of US/SLS-treated skin
QD untreated skin
(pmol) Dermis (pmol) Receiver (pmol) Total (pmol) a Dermis/Total
A 0.015 ± 0.006 0.115 ± 0.024 0.007 ± 0.006 0.122 ± 0.025 0.945 ± 0.045
B 0.113 ± 0.055 0.644 ± 0.098 0.044 ± 0.031 0.689 ± 0.095 0.935 + 0.043
C 0.195 ±0.055 1.054 ±0.218 0.244 ±0.039 1.311 ±0.239 0.800 ±0.026
D 0.042 ± 0.021 0.582 ± 0.236 0.006 ± 0.005 ' 0.587 ± 0.238 0.990 ± 0.006
a Total = Dermis + Receiver. These amounts are significantly greater than the QD amounts
quantified in the dermis of untreated skin (p < 0.05).
b In two of the individual skin samples included in this average, the amount of QDs in the
receiver chamber was below the quantification limit (see Section 4.2.6.1).
4.3.3 VISUALIZATION OF QD TRANSDERMAL PENETRATION PATHWAYS
Confocal microscopy was used to obtain images of selected skin regions of interest,
where QDs penetrated into the stratum comeum and the dermis. These images were used to
corroborate the ICP-MS results regarding QD penetration into the dermis and the receiver
chamber. Furthermore, these images provided qualitative information regarding the nature and
depth of QD penetration into US/SLS-treated skin and untreated skin. It is important to recognize
that the images presented here are regions of interest, in the sense that QD penetration was not
observed in the majority of the skin. Instead, QD fluorescence was localized in some hair
follicles (see FIGURE 4-1) and in regions with diameters typically on the order of 5 ptm, but
occasionally ranging up to 300 pm for untreated skin and up to 500 ptm for US/SLS-treated skin.
Furthermore, the regions of QD penetration were generally smaller and observed less frequently
in untreated skin compared to those in US/SLS-treated skin.
FIGURE 4-2 serves to highlight several aspects of QD transdermal penetration. Based on
FIGURE 4-2, one can observe that: (1) the intensity of the QD fluorescence in the surface of the
stratum comeum (see FIGURE 4-2B) and in the section of the dermis at a depth of 25 Pm (see
FIGURE 4-2D) of US/SLS-treated skin are both higher than those of untreated skin (see FIGURE
4-2A and FIGURE 4-2C, respectively). This corroborates the findings based on ICP-MS that
US/SLS treatment of the skin enhances QD penetration into the skin; (2) QDs penetrate into both
US/SLS-treated skin and untreated skin in localized regions (i.e. the distribution of QDs in the
skin is heterogeneous; additional examples are provided in FIGURE 4-3); (3) US/SLS treatment
increases the fractional surface area of skin through which QD penetration occurs (i.e. the
amount of red in FIGURE 4-2B and FIGURE 4-2D is greater than that in FIGURE 4-2A and FIGURE
4-2C, respectively); and (4) QDs penetrate into the dermis of untreated skin (see FIGURE 4-2C),
which provides visual confirmation of the ICP-MS result in TABLE 4-2. Observations (1) - (4)
were made for all four QDs studied. The number and size of QD penetration regions varied
among the QDs, but the discrete nature of QD skin penetration and the increased amount of QD
penetration into US/SLS-treated skin compared to that of untreated skin was consistently
observed for all four QDs studied.
Both FIGURE 4-4 and FIGURE 4-5 serve to corroborate the difference in ICP-MS results
for the penetration of the cationic QDs into US/SLS-treated skin (see Section 4.3.2). QD C was
observed to penetrate more deeply into the dermis (see the 55.0 pm depth image in FIGURE
4-4A). In addition, the QD fluorescence was observed in the bottom layers of the dermis (see
FIGURE 4-4B). This confirms the uptake of QD C into the deeper portions of the dermis, thus
corroborating the ICP-MS analysis which indicated the presence of these QDs in the receiver
chamber (see TABLE 4-2). On the other hand, while QD D was visually confirmed to penetrate
into the dermis, the fluorescence intensity decreased significantly with penetration depth (see
FIGURE 4-5A). QD D was observed in the bottom layers of US/SLS-treated skin (see FIGURE
4-5B). However, these regions of deep dermal penetration were small and difficult to find. Note
that only two regions of fluorescence are visible in FIGURE 4-5B, while hundreds of small
regions of fluorescence are visible in FIGURE 4-4B, indicating that QD C was more evenly
distributed throughout the bottom layers of the dermis. These observations are consistent with
the quantitative findings using ICP-MS which indicated that QD C reached the receiver chamber
in greater amounts compared to QD D.
Finally, in untreated skin, QDs were observed to penetrate into the dermis (e.g. see
FIGURE 4-6), but were not observed in the bottom layers of the dermis (not shown). This
corroborates the ICP-MS finding that without US/SLS enhancement, QDs did not reach the
receiver chamber in quantifiable amounts.
FIGURE 4-1: QD D penetration into US/SLS-treated skin in patches that were not limited to
within hair follicles. Optical section of the isolated dermis, made parallel to the epidermis-dermis
surface at a depth of 10 pm below the surface. The arrows indicate regions of QD penetration.
The image is an overlay of fluorescence and bright-field images. Bar = 200 pm.
Hair
FIGURE 4-2: Confocal images of selected regions of interest in the skin after 24 hours of QD
penetration into skin. (A) Surface of the stratum corneum after QD C penetration into untreated
skin, (B) Surface of the stratum comeum after QD C penetration in US/SLS-treated skin, (C)
Optical section of the isolated dermis, made parallel to the epidermis-dermis surface at a depth of
25 pm below the epidermis-dermis surface, after QD D penetration into untreated skin, and (D)
Optical section of the isolated dermis, made to a depth of 25 im below the epidermis-dermis
surface, after QD D penetration into US/SLS-treated skin. Brightness/contrast enhancement was
applied to (C) and (D). Bar = 200 ptm.
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FIGURE 4-3: Selected confocal images of QD transdermal penetration into US/SLS-treated skin.
Optical sections of the isolated dermis, made parallel to the epidermis-dermis surface. The depth
of each optical section ranges from 6 to 12 pm. Bar = 200 pm. (A) QD A, (B) QD B, (C) QD C,
(D) QD D. As can be seen, the distribution of QDs in the skin is heterogeneous.
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FIGURE 4-4: Confocal images of a selected region of interest in the isolated dermis after 24 hours
of QD C permeation across US/SLS-treated skin. (A) Optical sections parallel to the top dermis
surface (corresponding to 0.0 pm) to a depth of 55.0 ptm below the top dermis surface. (B)
Optical section from 30 ptm above the bottom dermis surface. Brightness/contrast enhancement
was applied to (B). Note that the thickness of the dermis is on the order of 600 pim. Bar = 200
pim.
FIGURE 4-5: Confocal images of a selected region of interest in the isolated dermis after 24 hours
of QD D penetration into US/SLS-treated skin. (A) Optical sections parallel to the top dermis
surface (corresponding to 0.0 pm) to a depth of 38.3 pm below the top dermis surface. (B)
Optical section from 30 pm above the bottom dermis surface. Brightness/contrast enhancement
was applied to (B). Note that the thickness of the dermis is on the order of 600 pm. Bar = 200
pm.
FIGURE 4-6: Confocal images of a selected region of interest in the isolated dermis after 24 hours
of QD C penetration into untreated skin. Optical sections from the dermis surface (corresponding
to 0.0 pm) to a depth of 50.0 pm below the dermis surface. Brightness/contrast enhancement was
applied. Bar = 200 tm.
4.4 DIscussioN
4.4.1 QD PENETRATION INTO UNTREATED SKIN
The permeation of rigid nanoparticles through untreated skin has previously been
investigated (e.g. [84,88-90,92,93]), and conflicting results have been reported. In particular,
some research groups claim that observations made using confocal microscopy show no
nanoparticle penetration beyond the stratum corneum of pig STS (e.g. [90,92]). Yet, others have
used confocal microscopy and qualitatively observed nanoparticle penetration into the dermis of
pig STS (e.g. [88,89]). In addition, in previous attempts at quantifying nanoparticle skin
penetration, no nanoparticles have been detected in the receiver chamber beneath pig STS using
either fluorescence measurements or elemental analysis [88,89]. Furthermore, there have been no
previous quantitative reports demonstrating nanoparticle penetration into the dermis of untreated
skin.
In the present study, the QDs were not detected to permeate untreated skin to reach the
receiver chamber, which is consistent with the previous findings described above. However, the
QDs did penetrate the dermis, which was quantified for the first time. Some previous reports
have claimed that nanoparticle penetration mainly occurs via hair follicles (e.g. [89,96]).
However, QD penetration into the dermis was observed in hair follicles as well as in localized
regions outside of hair follicles. To explain this observation, next, possible routes of passive
transdermal penetration of nanoparticles are discussed. One commonly proposed route is via
aqueous pores located in the head-to-head regions of the stratum corneum's lipid matrix
[50,88,89,93]. However, the QDs studied here are much larger than the reported average
effective aqueous pore diameter of untreated pig STS (3.3 nm [97]). Therefore, QD penetration
into the dermis via aqueous pores is unlikely. A more likely route of QD penetration is via
lacunar regions (imperfections [57]) present in the lipid bilayers of the stratum corneum. The
reported mean length of lacunar regions is 183.9 ± 95.03 nm, and the reported mean width is
48.1 ± 12.09 nm [57]. Therefore, the QDs may have permeated across the stratum corneum (the
major skin diffusion barrier) through these large lacunar regions. However, the area occupied by
these imperfections is small (area density, 0.44 ± 0.11% [57]), leading to the penetration of a
very small amount of QDs into the dermis of untreated skin, which was quantifiable by ICP-MS.
ICP-MS quantification limits were determined and confocal microscopy was used to visually
confirm that the amount of cadmium quantified in the dermis cannot be solely attributed to
contamination during sample preparation, to leaching of elemental cadmium from the QDs, or to
background cadmium amounts in the skin.
Next, commentary is provided on the conflicting reports in the literature about the ability
of nanoparticles to penetrate the dermis of untreated skin. Zhang et al. previously stated that the
failure to detect nanoparticles in the receiver solution indicates a lack of dermal absorption [89].
However, the combination of quantitative and qualitative results presented in this chapter (in
addition to previous qualitative results [88]) clearly shows that such an analysis is insufficient to
determine if nanoparticles can penetrate into the dermis. Furthermore, in the previous
applications of confocal microscopy to assess nanoparticle skin penetration, mechanical cross-
sections of the skin (i.e. sections made perpendicular to the skin surface) were examined by
confocal microscopy (e.g. [88-90,92]). However, since nanoparticle penetration was not
observed in the majority of the skin (i.e. nanoparticle penetration is heterogeneous), it is
anticipated that many cross-sections of the skin will not contain evidence of deep nanoparticle
penetration. In this approach, skin is typically prepared in 20-pm-thick sections, which makes it
practically impossible to thoroughly inspect the thousands of sections that can be theoretically
produced. Furthermore, since the sectioning knife that creates the cross-sections may
inadvertently transfer nanoparticles among the surfaces of the cross-sections, the volume of
dermis that can be inspected is reduced, which reduces the probability of observing nanoparticle
penetration. All of these reasons explain why this method of sample preparation has yielded
inconsistent results. The present study demonstrated that the nanoparticles studied indeed
penetrate the dermis in small, localized regions, which was observed after thorough inspection of
the intact dermis that was isolated after nanoparticles were applied to the skin. Therefore, the
method of inspecting the isolated, intact dermis for nanoparticle penetration is recommended
over inspecting mechanical cross-sections of the skin.
Finally, there are additional controversial areas in which the combination of sensitive
quantitative and qualitative methods may be applied. First, these methods can be used to address
hypotheses based on fluorescence measurements that nanoparticle penetration into human and
pig skin may be different, since it was observed that fluorescence measurements alone are
insufficient to address this topic (see Appendix, Section 4.7). Second, while QDs were utilized as
model nanoparticle drug carriers in this work, the results on the ability of nanoparticles to
penetrate into the dermis may also be interpreted in the context of nanoparticle toxicity. The
exposure of skin to nanoparticles is currently a controversial and sensitive topic because it would
have a significant impact on the regulation of several industries, e.g. waste management,
cosmetics, and personal care products [98]. The in vitro results in this chapter indicate that upon
applying an aqueous QD solution to skin for 24 hours, the QDs have the ability to penetrate into
the dermis. However, one must use caution when interpreting these results in the context of
nanoparticle toxicity. While the results may be concerning because the dermis is the vascularized
layer of the skin that can provide access for systemic absorption [88], it must be noted that the
exposure of skin to an aqueous solution for 24 hours is an extreme condition. In addition, water
is a penetration enhancer [99], and therefore, skin hydration may facilitate QD skin penetration.
Nevertheless, the application of the quantitative and qualitative methods described in this chapter
may be useful to address some of the conflicting reports in the field of nanoparticle skin toxicity.
4.4.2 QD PENETRATION INTO US/SLS-TREATED SKIN
The US/SLS skin treatment promoted the permeation of the QDs across the skin into the
receiver chamber in significant amounts, which was quantified using ICP-MS (see TABLE 4-2)
and visually confirmed by using confocal microscopy to observe QDs in the bottom layers of the
dermis (see FIGURE 4-4B and FIGURE 4-5B). In addition, while the majority of the QDs
penetrating past the epidermis remained in the dermis, it is important to recognize that, in vivo,
systemic transdermal drug delivery does not require permeation across the entire dermis layer
[49]. Indeed, once the blood capillaries near the epidermis/dermis junction are reached, the drug
can be delivered. The findings suggest that the US/SLS skin treatment represents a viable
method to significantly increase the penetration depth and quantity of nanoparticle carriers,
thereby enhancing the potential of nanoparticles to serve as useful transdermal drug carriers.
Next, commentary is provided on the extent of transdermal drug delivery enhancement
attained with the US/SLS skin treatment. In this study, the amount of QDs penetrating past the
epidermis of US/SLS-treated skin ranged from 1/oo1 to 1/1ooo of the amount in the aqueous
topical formulation (250 pmol). It is important to recognize that in this study, QDs served as
model nanoparticle drug carriers, and the efficacy of the US/SLS-enhanced transdermal delivery
method will depend on various factors that are application-specific, e.g. the US/SLS skin
treatment parameters, various physicochemical properties of the carriers (including size, charge,
hydrophilicity, and shape), the loading of the drug carrier, the drug potency, the amount of drug
required for therapeutic effect, and the topical formulation. All of these factors must be
considered in order to evaluate the viability of a particular US/SLS-enhanced transdermal drug
delivery application.
The ability of the QDs to fully permeate US/SLS-treated skin, and the discrete nature of
the QD penetration pathways into US/SLS-treated skin, can be explained by several
mechanisms: (1) the US/SLS skin treatment increases the area density, length, and connectivity
of the lacunar regions within the stratum corneum [57], (2) the US/SLS treatment increases the
average effective aqueous pore diameter of pig STS from 3.3 nm [97] to 22.6 nm [100], and (3)
the US/SLS treatment enhances skin permeability in a heterogeneous manner. Regarding (3), this
phenomenon of heterogeneity in US/SLS-treated skin has been well-documented in pig full-
thickness skin (FTS) [28,29]. Specifically, at an US frequency of 20 kHz, the US/SLS treatment
creates localized transport regions (LTRs; see Chapter 1, Section 1.4.3) with a reported average
effective aqueous pore diameter of greater than 60 nm [29]. The surrounding regions (referred to
as non-LTRs) have a reported average effective aqueous pore diameter of 3.7 nm [29]. Note that
untreated pig FTS and STS have similar pore diameters [97], and that US/SLS-treated pig FTS
and STS have similar pore diameters [100]. Therefore, it is reasonable to assume that the
distribution of LTRs and non-LTRs (and their respective pore diameters) within FTS and STS
are similar. Next, this assumption is used in order to discuss the results.
First, in ref [29], US/SLS treatment was applied to pig FTS to attain three skin electrical
resistivity values of 0.8, 0.6, and 0.5 kM cm 2. Skin samples treated to 0.8 kfQ cm2 had an average
LTR fractional area of 11%, which varied inversely with skin electrical resistivity [29]. In the
present study, skin samples were treated to attain electrical resistivities of 1.25 ± 0.25 ki cm2,
which required less US/SLS treatment than that utilized in ref. [29]. Therefore, one can safely
over-estimate the fractional area of LTRs in the present study to be 11%. This implies that the
non-LTRs occupied at least 90% of each US/SLS-treated skin sample. Since the non-LTRs
occupy the majority of the skin, and since the reported non-LTR average pore size (3.7 nm [29])
is much smaller than the size of the QDs studied here (10 - 20 nm), the finding that QD
penetration was not observed in the majority of the skin (corresponding to non-LTRs) is
reasonable.
Second, the reported LTR pore size of > 60 nm [29] explains why the QDs were able to
penetrate US/SLS-treated skin in localized regions. The observation of the QDs penetrating the
dermis (see FIGURE 4-3, FIGURE 4-4, and FIGURE 4-5) provides visual support to the previously
proposed hypothesis that LTRs dominate transdermal transport even in the dermis [33]. As
suggested previously, the transformation of LTR formation from a heterogeneous to a
homogeneous phenomenon has the potential to further enhance the transdermal penetration of
macromolecules [28], including nanoparticles.
4.4.3 EFFECT OF SURFACE CHARGE ON QD TRANSDERMAL PENETRATION
It has previously been shown that cationic nanoparticles have an affinity for the
negatively-charged skin pores, in contrast to anionic nanoparticles, when they are applied to
untreated skin [88,90]. Based on these previous findings, one might expect QD D to penetrate
skin in greater amounts compared to QDs A - C. However, it has been quantitatively and
qualitatively demonstrated that among the four QDs studied, the QD that exhibited the greatest
ability to penetrate both untreated skin and US/SLS-treated skin was not the most cationic QD.
This suggests that there is an optimum cationic surface charge for nanoparticle skin penetration.
A nanoparticle that is too cationic may experience hindered diffusion due to strong electrostatic
interactions with the negatively-charged skin. Furthermore, the two cationic QDs (C and D)
exhibited very different behaviors once they penetrated past the epidermis; out of the four QDs
studied, QDs C and D exhibited the smallest and largest fractional retentions in the dermis,
respectively. This result was corroborated by FIGURE 4-4 and FIGURE 4-5, which show that QD C
more readily penetrated into the deep layers of the dermis compared to QD D. Therefore, surface
charge plays a role in the penetration depth of the nanoparticle. In future studies, one may want
to optimize the nanoparticle surface charge such that the nanoparticle drug carrier penetrates the
skin at sufficient depths and in sufficient quantities. The desired nanoparticle penetration depth
will differ for systemic and topical drug delivery applications. For topical applications, perhaps,
a drug carrier's surface charge can be tuned to target specific entities found at different depths
within the skin.
Finally, QD A penetrated both untreated skin and US/SLS-treated skin in the smallest
amounts, in spite of being smaller than the other QDs. Therefore, the findings strongly suggest
that the anionic surface charge is the least favorable for nanoparticle skin penetration, which is
consistent with previous experimental findings [88,90]. In addition, this result is consistent with
the theoretical finding that a charged particle diffusing through a pore of like charge will
experience reduced mobility compared to a neutral particle of the same size [101]. Because the
skin pores are negatively charged, anionic nanoparticles are expected to permeate the skin in
smaller amounts compared to neutral ones.
4.5 CONCLUSIONS
In this study, sensitive, complementary, quantitative and qualitative methods were
utilized to evaluate the delivery of nanoparticles into the dermis. These methods will be useful in
future assessments of nanoparticle skin penetration. Using ICP-MS, QD penetration into the
dermis of untreated skin was quantified for the first time. In addition, confocal microscopy was
utilized in a manner that allows for an improved assessment of dermal penetration compared to
previously published methods, and QDs were observed to penetrate skin heterogeneously. ICP-
MS and confocal microscopy were combined to show that the US/SLS skin treatment can
significantly enhance the skin penetration of nanoparticles, thereby enhancing the potential of
nanoparticles to serve as transdermal drug carriers. Unexpectedly, the QD that exhibited the
greatest skin penetration was not the most cationic QD. In addition, the most cationic QD studied
exhibited the lowest clearance from the dermis of US/SLS-treated skin. These findings suggest
that an optimum surface charge exists for nanoparticle skin penetration, and motivate the
application of nanoparticle carriers to US/SLS-treated skin for enhanced transdermal drug
delivery.
In this chapter, it was demonstrated that the proper application of fluorescence techniques
can lead to new insights when used in conjunction with a quantitative method. In the next
chapter, then, this concept was applied to gain new insights into the mechanisms of chemical
penetration enhanced transdermal drug delivery. Chapter 5 describes the first study of
fluorescent penetration enhancers (FPEs) and demonstrates the combination of FPEs with
fluorescence technologies to directly visualize the behavior of FPEs within skin. New insights
obtained using this approach will aid in designing effective penetration enhancers for drug
delivery applications.
4.6 APPENDIX A: DETAILED ICP-MS PROTOCOLS
4.6.1 CLEANING PROTOCOLS
These protocols were used to meticulously clean the glassware, stir bars, and polyfluor alkoxy
vials (Savillex, Minnetonka, Minnesota) in order to reduce background amounts of metal that
would otherwise interfere with the quantification of trace cadmium amounts from the quantum
dots that penetrated into the skin.
4.6.1.1 GLASSWARE
1. Place diffusion cell donor and receiver chambers in a base bath (lM NaOH in 50 vol%
ethanol) for 4 hours.
2. Rinse cells with de-ionized (DI) water.
3. Place cells in 1 N HCl (reagent grade) overnight.
4. Rinse cells with DI water.
5. Sonicate cells in DI water for 99 minutes.
6. Rinse cells with DI water. Refill bath sonicator with clean DI water.
7. Sonicate cells again in DI water for 99 minutes.
8. Rinse cells, and let cells sit in DI water overnight.
9. Rinse and dry cells.
4.6.1.2 STIR BARS
1. Place stir bars in a small vial and add 1 N HCl (reagent grade).
2. Sonicate the vial for 99 minutes.
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3. Rinse the vial contents with DI water and refill with DI water.
4. Sonicate for 99 minutes.
5. Rinse the vial contents with DI water.
6. Place the vial on a stir-plate and stir vigorously.
7. Rinse the stir bars with DI water.
4.6.1.3 POLYFLUOR ALKOXY (PFA) VIALS FOR ICP-MS
Note: Polyfluor alkoxy (PFA) vials should not be cleaned in the base bath.
1. Perform this step if PFA vials are greasy. Leave vials in aqua regia for 1 day over
medium heat. Rinse with DI water.
2. Rinse vials with mega-pure water.
3. Place vials in a large jar for leaching.
4. Fill the jar with 1 N HCl (reagent grade).
5. Cap and invert the jar several times.
6. Triple-bag the jar so that any evaporated acid will not damage the oven.
7. Place the jar in an oven at 60*C for 2 days.
8. Take the jar out of the oven using gloves and place in a hood to cool down for 2 hours.
9. Pour out the HCl from the jar.
10. Rinse the jar with mega-pure water, twice.
11. Remove the vials and rinse vials individually with mega-pure water.
12. Fill the vial bottoms to the brim with 0.1N HCl (ultra grade) and cap with the vial tops.
13. Place the vials into a glass jar.
14. Place the jar in an oven at 60*C for 1 day.
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15. Using gloves, turn the jar upside down and leave the jar in the oven for an additional day.
16. Remove the jar from the oven using gloves and let cool.
4.6.2 DIGESTION PROTOCOLS
In these protocols, samples are digested in preparation for trace-metal analysis. All HCl solutions
in this procedure should be ultra grade.
4.6.2.1 DIGESTION OF DERMIS SAMPLES
1. Discard the 0. IN HCl that is remaining in the 22-mL PFA vials from the cleaning step.
2. Add dermis samples to the PFA vials using a clean pipette tip for each sample. Prepare
one control PFA vial for background cadmium amounts (without adding skin to the vial).
3. Withdraw a 1 mL pipette tip and rinse the tip 3x in 1% HCl and 3x in 0.01% HCl to
minimize trace metal contamination.
4. If an intermediate container was used to transfer the dermis sample to the PFA vial, add 1
mL 70% HNO3 to the intermediate container to collect any residual cadmium. Close the
intermediate container and shake well. Then, pour the contents into the appropriate PFA
vial.
5. Add 70% HNO3 to each PFA vial to attain a final volume of 3 mL. That is, if 1 mL was
used to rinse an intermediate container, add 2 mL. Otherwise, add 3 mL.
6. Cap each PFA vial tightly and swirl. Transport vials to a hood within a clean room.
7. Place PFA vials onto a hotplate heated to 100-110*C for two days. Note that during this
step, the samples are being digested.
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8. Turn off the hotplate and wait at least 15 minutes for the vials to cool down. Uncap the
vials and set the hotplate to 60'C to evaporate the samples to dryness (takes up to 6
hours).
4.6.2.2 DIGESTION OF RECEIVER SOLUTION SAMPLES
1. Discard the 0. IN HCl that is remaining in the 60-mL PFA vials from the cleaning step.
2. Add dialyzed receiver solution samples to the PFA vials. Transport vials to a hood within
a clean room.
3. Place PFA vials (uncapped) onto a hotplate heated to 600C for 6 hours, or until vial
contents are evaporated.
4. Add 5 mL 70% HNO3 to each vial. Prepare one control PFA vial for background Cd
amounts (containing only 5 mL 70% HNO3). Cap the vials.
5. Place PFA vials onto a hotplate heated to 100-110C for two days. Note that during this
step, the samples are being digested.
6. Turn off the hotplate and wait at least 15 minutes for the vials to cool down. Uncap the
vials and set the hotplate to 600 C to evaporate the samples to dryness (takes up to 6
hours).
4.6.3 GENERAL RE-DISSOLUTION PROTOCOL
After the samples are digested, the samples are redissolved into a specified volume of dilute acid
according to the general protocols described below. In each protocol, the volume of acid was
selected to minimize clogging of the ICP-MS equipment by skin particulates and to maximize Cd
detection. All HCl solutions in this protocol should be ultra grade. All conical tubes should be
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"metal-free" grade. As described below, all samples were spiked with a standard indium salt
solution to ensure the accuracy and precision of the ICP-MS method.
o Untreated dermis. Add 5 mL 1% HNO3 to PFA vials. Heat vials at 60'C for 5 minutes,
then swirl the vials to re-dissolve their contents. Then, transfer 1 mL of the vial contents
to a 15 mL conical tube containing 4 mL 1% HNO 3. Note that this protocol is equivalent
to dissolving the sample in 25 mL of 1% HNO3. Add 25 [tL indium standard to the conical
tube to attain a final concentration of 1 ppb. This protocol is described in detail below.
o US/SLS-treated dermis. Add 5 mL 1% HNO3 to PFA vials. Heat vial at 60'C for 5
minutes, then swirl the vials to re-dissolve their contents. Then, transfer 0.5 mL of the vial
contents to a 15 mL conical tube containing 4.5 mL 1% HNO3. Note that this protocol is
equivalent to dissolving the sample in 50 mL of 1% HNO 3. Add 25 pL indium standard to
the conical tube to attain a final concentration of 1 ppb.
o All receiver solution samples. Add 10 mL 1% HNO 3 to PFA vial. Heat vial at 60'C for 5
minutes, then swirl the vials to re-dissolve their contents. Then, transfer all of the vial
contents to a 15 mL conical tube and add 50 pL indium standard to attain a final
concentration of 1 ppb.
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Example detailed protocol for re-dissolving untreated dermis:
1. Rinse a pipette tip 3x in 1% HCl and 3x in 0.01% HCl to minimize trace metal
contamination.
2. Add 4 mL 1% HNO3 to all Falcon tubes.
3. Add 5 mL 1% HNO3 to all PFA vials.
4. Cap PFA vials and shake. Open and check for undissolved residues.
5. Place vials onto a hotplate heated to 60'C for 5 minutes. Swirl the vials and ensure that
all solids are dissolved.
6. For each sample, rinse a new pipette tip with the PFA vial contents. Transfer 1 mL of the
PFA vial contents to a Falcon tube. Pipette up and down to mix well.
7. Rinse a new pipette tip 3x in 1% HCl and 3x in 0.01% HCl. Add 25 pL indium standard
to all tubes to attain a final concentration of 1 ppb.
8. Vortex all tubes.
9. At this point, samples are ready to be injected into the ICP-MS. If necessary, the samples
can be filtered to remove skin particulates, which will minimize clogging of the ICP-MS.
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4.7 APPENDIX B: QD FLUORESCENCE QUENCHING IN THE PRESENCE OF SKIN
4.7.1 MATERIALS AND METHODS
An area of 700 ptm-thick pig STS equal to the area available for QD diffusion (1.77 cm 2
was isolated and solubilized using 5 mL of Soluene*-350 (PerkinElmer, Waltham,
Massachusetts). This was repeated using 700 [tm-thick human STS; human STS was prepared as
described in Chapter 3, Section 3.2.2. Then, QD C was added to the following three solutions to
attain a QD concentration of 68 nM: (1) Soluene, (2) pig skin in Soluene, and (3) human skin in
Soluene. In addition, control skin/Soluene solutions were prepared. A SPEX FluoroMax-3
spectrofluorimeter (HORIBA Jobin Yvon, Edison, New Jersey) was used to excite each sample
at 350 nm and to measure the fluorescence intensity at 600 nm (the peak emission wavelength of
QD C).
4.7.2 RESULTS AND DISCUSSION
The normalized fluorescence intensities of the QD solutions were significantly greater
than those of the control solutions (see FIGURE 4-7). In addition, both pig and human skin were
found to quench QD fluorescence, however the emission of the QD/Pig/Soluene solution is
significantly greater than that of the QD/Human/Soluene solution (p < 0.05). These results
indicate that QD fluorescence quenching can be more prominent in human skin than in pig skin.
This is likely to be caused by differences between the pig and human skin components [102].
These results are reported because there are arguments in the literature that pig skin is more
permeable to nanoparticles than human skin (e.g. [98,103]). These arguments are based on
comparisons of nanoparticle fluorescence intensities within pig and human skin. However, the
results indicate that fluorescence measurements are insufficient to compare nanoparticle
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penetration into pig and human skin. Furthermore, these results explain why smaller nanoparticle
fluorescence intensities have been observed within human skin compared to pig skin. A
quantitative method such as ICP-MS is suggested to more accurately evaluate whether pig and
human skin models are equally permeable to nanoparticles.
Q l 'n """"""""" """""""" """"""""
QD/Soluene QD/Pig/Soluene QD/Human/Soluene Human/Soluene
"""""
Pig/Soluene
FIGuRE 4-7: Fluorescence intensities of QD/Skin/Soluene solutions, normalized with respect to
that of the QD/Soluene solution. Data shown are the mean ± SD of two replicates.
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CHAPTER 5
FLUORESCENT PENETRATION ENHANCERS
FOR TRANSDERMAL APPLICATIONS
5.1 INTRODUCTION
Chemical penetration enhancers (referred to hereafter as penetration enhancers) are
molecules that facilitate drug delivery through a biological membrane. These membranes are
often composed of lipid assemblies, including the stratum corneum of the skin, epithelial
membranes (e.g. corneal, buccal, and intestinal), and cellular membranes. Many molecules have
been identified that can enhance drug delivery [14,104-107], particularly amphiphiles, which are
molecules that contain polar moieties ("head" groups) and non-polar moieties ("tail" groups).
Unfortunately, potent penetration enhancers are often also potent irritants [106]. Several
investigations have been carried out to elucidate the molecular mechanisms involved in
penetration enhancement and in membrane irritation (primarily regarding transdermal drug
delivery [14,106,107], the focus of this thesis). For example, proposed transdermal enhancement
mechanisms include extraction or fluidization of lipid bilayers, formation of segregated phases
within the bilayers, and others [14]. However, the mechanisms are still not fully understood.
Accordingly, the development of new approaches to evaluate the interactions between
penetration enhancers and biological membranes would significantly contribute to a better
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understanding of the mechanisms involved. In turn, this would aid in designing potent, yet safer,
penetration enhancers for drug delivery.
In the life sciences, the generalized problem of studying the behavior of molecules within
biological tissues has often made use of fluorescence-based techniques. Using techniques such as
fluorescence resonance energy transfer (FRET), time-resolved fluorescence (TRF), fluorescence
polarization (FP), fluorescence recovery after photobleaching (FRAP), fluorescence correlation
spectroscopy (FCS), fluorescence lifetime imaging microscopy (FLIM), and confocal and multi-
photon fluorescence microscopy, one can study structure, function, and interactions of molecules
in biological systems [108]. These well-established techniques require that the molecules of
interest be either naturally fluorescent or fluorescently-labeled.
To the best of our knowledge, penetration enhancers have never been synthetically
modified with a fluorescent label, presumably because it is believed that the relatively large size
of fluorescent labels would significantly affect the activity of the enhancers. Therefore, the goal
of this work was to identify naturally fluorescent penetration enhancers (FPEs) in order to utilize
fluorescence technologies to directly study the behavior of FPEs within the skin for the first time.
In this study, 12 FPE candidates with amphiphilic characteristics (see Section 5.2.1) were
selected and ranked according to their potency as skin penetration enhancers. Because
amphiphiles are known to adsorb at an oil/water interface, and thereby to lower the interfacial
tension, oil/water interfacial tension measurements were carried out to assist in analyzing and
interpreting the results. In addition, based on the determined ranking, FPE design principles are
discussed for future studies.
Subsequently, two-photon fluorescence microscopy (TPM) was used to directly visualize
and compare the skin penetration profiles of FPE candidates that ranked high and low as
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transdermal FPEs. In addition, TPM was used to demonstrate that new insights can be obtained
by directly visualizing the behavior of FPEs within skin. In transdermal applications, penetration
enhancers are often part of a multi-component skin treatment or topical formulation that is
designed to overcome the skin barrier in a safe and effective manner. FPEs can now be used to
visualize the effect of skin treatments on FPE penetration into skin. This chapter presents the first
direct visualization of passive, glycerol-mitigated, and ultrasound-assisted FPE penetration into
skin. The glycerol and ultrasound (US) treatments are well-established skin treatments that are
utilized for decreasing and increasing skin penetration, respectively. Glycerol, a well-known skin
moisturizer (humectant), is often used in combination with irritating substances in order to
mitigate irritation [109]. On the other hand, low-frequency US is a physical skin penetration
enhancer that is often combined with chemical enhancers, resulting in synergism in enhancing
transdermal drug delivery [27,30,97]. TPM has previously been used to study the effect of these
two skin treatments on penetration enhancers by treating skin either simultaneously or
successively with a penetration enhancer and a fluorescent probe in order to indirectly visualize
the effects of the penetration enhancer on the skin [21,54,110]. Similarly, dual-channel TPM
(which allows for the simultaneous imaging of an exogenous fluorescent probe and the intrinsic
skin fluorophores [111]) has previously been used to delineate penetration enhancer-induced
changes in permeant diffusion with respect to the skin structural features [54,110,111]. These
effects can now be directly visualized and investigated using FPEs.
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5.2 MATERIALS AND METHODS
5.2.1 SELECTION OF FLUORESCENT PENETRATION ENHANCER (FPE) CANDIDATES
Many potent penetration enhancers are amphiphiles [14,104-107]. Therefore, 12
molecules that have amphiphilic characteristics were selected as FPE candidates. Fluorescent
molecules with various head group chemistries, tail group lengths, and fluorophores were
selected as FPE candidates. A list of these 12 molecules is provided in TABLE 5-1, and the
corresponding chemical structures are shown in FIGuRE 5-1. Molecules 1 - 4 were selected
because they are fluorescent and exhibit the following additional desirable features which are
favorable for penetration enhancers: (i) long, saturated, unbranched hydrocarbon chains (or tail
groups) [112], and (ii) low molecular weight (less than 500 Daltons) [113]. Molecule 5 was
selected because it is one of a handful of fluorescent dyes that is marketed as an amphiphile; this
one was selected because of its relatively low molecular weight among amphiphilic dyes.
Molecule 6 was selected because it is fluorescent, has a low molecular weight, and was
determined to be surface-active in our preliminary experiments (using the procedure described in
Section 5.2.7, molecule 6 lowered the oil/water interfacial tension by 2.8 ± 0.5 mN/m (95%
confidence interval)).
Molecules 7 - 12 are all rhodamine derivatives. The selection of these molecules was
inspired by recent findings by Polat et al. regarding the amphiphilic nature of the fluorescent
dye, sulforhodamine B (SRB) [114]. SRB has repeatedly been utilized as a hydrophilic dye.
However, SRB is actually an amphiphile, despite being a bulky molecule. SRB was shown to act
as a penetration enhancer when combined with a low-frequency US skin treatment (low-
frequency US is a physical skin penetration enhancer [27,30]). However, in preliminary passive
experiments (without US), SRB was determined to be an insignificant penetration enhancer (as
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will be shown in Section 5.3.1). It was hypothesized that without US, SRB is too bulky to
penetrate into skin in significant amounts, and that smaller rhodamine derivatives may better
penetrate into skin and may be mischaracterized in the literature as hydrophilic instead of
amphiphilic (as was the case with SRB). Therefore, several rhodamine derivatives whose
molecular weights are smaller than that of SRB were selected as FPE candidates.
5.2.2 SOURCES OF FPE CANDIDATES
Acridine orange 10-nonyl bromide (AO), methyl orange sodium salt (MO), rhodamine
110 chloride (RI 10), rhodamine B chloride (RB), and SRB sodium salt were obtained from
Sigma-Aldrich (St. Louis, Missouri). 5-dodecanoylaminofluorescein (FLUOR), BODIPY*
500/510 C8 , C5 (BODIPYl), and BODIPY* FL C11 (BODIPY2) were obtained from Invitrogen
(Carlsbad, California). Rhodamine 6G chloride (R6G) was obtained from Acros Organics (Geel,
Belgium). Sulforhodamine G sodium salt (SRG) was obtained from Biotium (Hayward,
California). 5-carboxytetramethylrhodamine (TAMRA) was obtained from ChemPep
(Wellington, Florida). 2-{3-Cyano-4-[4-(dodecyl-methyl-amino)-phenyl]-5,5-dimethyl-5H-
furan-2-ylidene}-malononitrile (DCDHF) was a gift, synthesized at Kent State University, Kent,
Ohio. MO, RB, and SRG were purified via Biichner funnel vacuum filtration in order to remove
water-soluble impurities prior to use (see Section 5.2.4). All the other FPE candidates were used
as received.
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TABLE 5-1: Name and molecular weight (MW) of each of the 12 FPE candidates. Chemical
structures are provided in FIGURE 5-1.
Acronym Name MW (Da) Structure
AO acridine orange 1 0-nonyl bromide 473 1
BODIPY1 BODIPY* 500/510 C8, C5  404 2
BODIPY2 BODIPY* FL C11  404 3
DCDHF 2-{3-Cyano-4-[4-(dodecyl-methyl-amino)-phenyl]-5,5- 459 4dimethyl-5H-furan-2-ylidene}-malononitrile
FLUOR 5-dodecanoylaminofluorescein 530 5
MO methyl orange, sodium salt 327 6
RB rhodamine B chloride 479 7
R6G rhodamine 6G chloride 479 8
R110 rhodamine 110 chloride 367 9
SRB sulforhodamine B, sodium salt 581 10
SRG sulforhodamine G, sodium salt 553 11
TAMRA 5-carboxytetramethylrhodamine 430 12
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FIGURE 5-1: Chemical structures of the fluorescent penetration enhancer (FPE) candidates.
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5.2.3 SOURCES OF GENERAL CHEMICALS
Phosphate buffered saline (PBS) tablets, 1-octanol, and sodium lauryl sulfate (SLS) were
obtained from Sigma-Aldrich (St. Louis, Missouri). PBS was prepared from PBS tablets
according to the manufacturer's instructions. Glycerol was obtained from Mallinckrodt Baker
(Paris, Kentucky). 200 proof ethanol was obtained from EMD Chemicals (Gibbstown, New
Jersey). 99+% n-decane was obtained from TCI America (Portland, Oregon). Deionized water
dispensed from a Milli-Q academic water purification system (Millipore, Bedford,
Massachusetts) was used to prepare all solutions. All general chemicals were used as received.
5.2.4 PURIFICATION OF MO, RB, AND SRG FROM WATER-SOLUBLE IMPURITIES
MO, RB, and SRG were purified by the following procedure in order to separate them
from water-soluble impurities. First, these molecules were added to vials containing water,
which were subsequently heated to 60*C and then sonicated. After even dispersions were
obtained, which usually occurred within 20 minutes, vials were transferred to a salt water/ice
bath. Solutions were allowed to recrystallize for 30 minutes. Then, solutions were vacuum-
filtered using a Bfichner funnel and Grade 1 filter paper (Whatman, Piscataway, New Jersey).
Retentates were rinsed several times with water and then dried in an oven overnight at 70*C.
5.2.5 GENERAL PROTOCOL FOR DIFFUSION EXPERIMENTS
The following methods have been described in Chapter 3, Sections 3.2.2 and 3.2.3.
Briefly, pig skin was obtained from E.M. Parsons & Sons (Hadley, Massachusetts) according to
a protocol which was approved by the Committee on Animal Care at MIT. Human cadaver skin
was obtained from National Disease Research Interchange (Philadelphia, Pennsylvania). Skin
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samples were prepared to a thickness of 700 pm and then mounted into Franz diffusion cells
(PermeGear, Hellertown, Pennsylvania) consisting of a donor chamber and a receiver chamber.
Any skin sample having an initial electrical resistivity of < 50 kW cm2 (measured with PBS in
both chambers) was considered damaged and was discarded.
Subsequently, for all the 24-hour diffusion experiments described below, the PBS
solution in the donor chamber was exchanged for 40:60 (by volume) ethanol:PBS (referred to
hereafter as 40% ethanol) containing the specified solute concentration. Note that 40% ethanol
was used in order to solubilize all the FPE candidates. The donor chamber was sealed using
parafilm, and the diffusion cell was covered with aluminum foil to minimize photobleaching.
Experiments were conducted at room temperature (25*C).
5.2.6 EVALUATING THE POTENCY OF THE FPE CANDIDATES
The potency of the FPE candidates was quantified by the skin current enhancement ratio
(ER), based on previous methods for screening penetration enhancers [106,107,115]. 1 mM FPE
candidate solutions were applied to pig skin (for DCDHF, 0.02 mM was used due to low
solubility). Initial skin currents were measured 10 - 15 minutes after the start of the experiment
in order to obtain stable current measurements [115]. Final skin currents were measured after 24
hours. The ER is defined as the ratio of the final to the initial skin currents. Note that both
currents were measured through the 40% ethanol solution present in the donor chamber. 1 mM
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SLS (a well-known potent penetration enhancer) was used as the positive control, and 40%
ethanol was used as the negative control*.
5.2.7 OIL/WATER INTERFACIAL TENSION MEASUREMENTS
The interfacial tension between water and decane, in the presence and absence of solute,
was measured based on a previously published method [119]. For each solute, a 2 mM aqueous
solution was prepared. Decane was added to attain a volume ratio of 1:1. The interfacial tension
was measured at 25 ± 1C with a Kriss K 11 tensiometer and a platinum ring (Hamburg,
Germany), using the "interfacial pull" method as described in the instrument manual. The
following speeds were used for the various movement steps in the measuring procedure: (i)
"measuring", 10 mm/min, (ii) "immersion", 10 mm/min, and (iii) "search", 2 mm/min.
Measurements were taken every 20 - 30 seconds until equilibrium was attained, which typically
required 1 -2 hours. The final 10 measurements were averaged for each sample. The lowering of
interfacial tension is reported as the absolute difference between the oil/water interfacial tension
values in the presence and in the absence of solute. SLS was used as a positive control.
Measurements were carried out in triplicate.
* It was observed that the negative control ERs exhibited by pig skin harvested in November and December were
significantly greater than those reported in this chapter (which were measured using pig skin harvested in earlier
months in the year). This may be explained due to seasonal variation in skin permeability [116-118]. Therefore, only
pig skin batches that yielded low negative control ERs were utilized in this study (i.e. skin from November-
December were not used), so that the penetration enhancement induced by the 40% ethanol would not mask the
enhancement induced by the FPE candidates.
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5.2.8 TWO-PHOTON MICROSCOPY (TPM) CASE STUDY METHODS
The purpose of these case studies was to use two-photon fluorescence microscopy (TPM)
to demonstrate several applications where the direct visualization of FPEs within skin can
provide new physical insight. Specifically, the following applications are demonstrated: (I)
comparison of the skin penetration profiles of a significant and an insignificant penetration
enhancer, (II) visualization of the effect of skin treatments on increasing and decreasing skin
penetration, and (III) simultaneous imaging of a FPE and the skin structure.
First, a rationale is provided for selecting which FPE candidate should be used to
demonstrate applications I - III. As will be shown in Section 5.3.1, SRB ranked the lowest in
potency out of the 12 FPE candidates evaluated. Since the chemical structure of SRB is similar
to that of SRG (see FIGURE 5-1), which exhibited potency similar to that of SLS (see Section
5.3.1), TPM was used to independently substantiate the interesting findings involving SRB and
SRG (application I). Subsequently, SRG became a convenient choice to demonstrate glycerol-
mitigated and ultrasound-assisted FPE skin penetration (application II) because baseline images
of SRG skin penetration were already obtained for application I. Finally, SRG is the most potent
FPE whose fluorescence could be filtered from that of the skin for dual-channel TPM imaging
(application III).
5.2.8.1 PREPARATION OF SKIN SAMPLES FOR TPM IMAGING
For SRB-treated skin (application I), 1 mM SRB was applied to pig skin for 24 hours. For
SRG-treated skin (applications I and II), 1 mM SRG was applied to pig skin for 24 hours. For
skin treated with SRG and glycerol (application II), the donor solution was prepared as follows:
(1) glycerol was added to 40% ethanol to attain 10 wt% glycerol (5 - 15 wt% glycerol is
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commonly used in studies on the role of glycerol in cosmetic and pharmaceutical formulations
[120]), and (2) SRG was subsequently added to attain 1 mM SRG. For skin treated with SRG
and US (application II): ultrasound, with the solid probe tip immersed in a coupling medium
containing 1 mM SRG in 40% ethanol, was applied to pig skin with a VCX 130 (Sonics &
Materials, Newtown, Connecticut) at the following ultrasound parameters [29]: frequency - 40
kHz, intensity - 7.3 W/cm2 (for a coupling medium of 40% ethanol, this corresponds to a 40%
amplitude setting, as verified using calorimetry), pulsing - 5 seconds on, 5 seconds off, tip
displacement - 3 mm, treatment time - 2 minutes ("on" time). The coupling medium was
replaced at least every 30 seconds to reduce thermal effects. Note that the duration of the SRG
and US treatment was 4 minutes (taking into account the US pulsing), while the duration of all
the other skin treatments was 24 hours.
For dual-channel TPM imaging (application III), 2 g/mL (3.6 pM) SRG was applied to
human skin for 24 hours. The dilution of SRG (compared with 1 mM for applications I and II)
reduces the SRG fluorescence signal such that it is comparable with that of the skin, which
enables the detection of both signals. Note that human skin was used for application III because
it is the most commonly used skin model for dual-channel TPM imaging [54,111].
Immediately following the end of each skin treatment, the skin surface was rinsed with
40% ethanol and blotted with a kimwipe to remove excess solute. The treated skin area was
isolated using scissors and inserted into an imaging chamber (Coverwell PCI-A-0.5, Grace Bio-
Labs, Bend, Oregon) with PBS as the mounting medium. The imaging chamber was sealed with
a No. 1.5 glass coverslip.
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5.2.8.2 TPM IMAGING
Images were obtained on a Zeiss LSM 510 microscope using a 63x oil objective and a
Spectra-Physics Mai Tai laser tuned to 780 nm. TPM imaging was conducted based on
previously published methods [54,111,121]. The following settings were used for the three TPM
applications: (a) for SRB-, SRG-, and SRG/glycerol-treated pig skin, the laser power was
measured at the sample to be 0.4 mW. Emission wavelengths < 685 nm were collected.
Configurations were set such that in the absence of fluorophores, no signal was detected, (b) for
SRG/US-treated pig skin, the laser power was 0.7 mW for imaging 0 - 20 tm below the skin
surface and 5 mW for imaging depths > 20 ptm. Emission wavelengths in the range of 565 - 615
nm were collected. Configurations were set such that in the absence of SRG, no signal was
detected, and (c) for dual-channel imaging of SRG and human skin autofluorescence, the laser
power was 34 mW. In the "green" channel, emission wavelengths < 515 nm were collected
(corresponding to skin autofluorescence [122]). In the "red" channel, emission wavelengths in
the range of 565 - 615 nm were collected (corresponding to SRG fluorescence). Using the stated
experimental conditions and microscopy configurations, the skin autofluorescence intensities in
the presence and in the absence of SRG were found to be comparable, thus verifying that SRG
did not introduce noise in the green channel. Configurations were set such that in the absence of
SRG, no signal was detected in the red channel (see FIGURE 5-2).
Up to six 200 pm x 200 pm sites were imaged within each skin sample. Images were
obtained in the plane parallel to the skin surface (xy-mode), and optical sections were made in
the z-stack mode (e.g. see FIGURE 5-3). In all the figures presented, a red color scheme is utilized
to illustrate routes of FPE penetration. It is important to recognize that the images serve to
provide qualitative information regarding the visualization of FPE penetration patterns.
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FIGURE 5-2: Representative dual-channel control images of human skin autofluorescence at the
skin surface. 40% ethanol (without SRG) was applied to the skin for 24 hours. Left column, SRG
channel; right column, skin autofluorescence channel (the presence of skin fluorophores is
indicated by the green color). Bar = 20 pm.
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FIGURE 5-3: Representative series of optical sections of SRG penetration into the top 20 pm of pig skin. The presence of SRG is
indicated by the red color. Note that the series of images ("z-stack") is scanned at a single site (i.e. the x/y-coordinates are fixed while
the z-coordinate increases by 1 gm between scans). The z-stack shows that SRG penetration decreases with skin depth. Bar = 20 pm.
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5.2.8.3 IMAGE ANALYSIS
Images were analyzed using ImageJ software (National Institutes of Health, Bethesda,
Maryland) [95]. The "Plot Z-axis profile" function was used to calculate the average
fluorescence intensity vs. skin penetration depth from each series of images obtained in the z-
stack mode (e.g. FIGURE 5-3). These data were averaged over all of the sites imaged for each skin
treatment. In addition, for all figures, the brightness and contrast of the images was adjusted first
by using the "Auto" feature in order to enhance the visibility of the regions of FPE penetration,
and second by increasing the minimum displayed pixel value. These adjustments were
propagated to control images to ensure that the control images remained black.
It is very important to recognize that SRB fluoresces more brightly than SRG in non-
polar environments (for details, see below)*. Therefore, in order to compare the penetration of
SRB and SRG into skin, the SRB fluorescence intensities were normalized by the ratio of the
SRB and SRG fluorescence intensities within PBS-saturated octanol (a common chemical model
for the skin's lipid bilayers [123], where SRB and SRG localized as shown in FIGURE 5-4).
The normalization constant was calculated after the following experiment was performed
in triplicate for SRB and for SRG. 20 p.L of the 1 mM donor solution was added to 7 mL of PBS-
saturated octanol. After the solution was sonicated, a SPEX FluoroMax-3 spectrofluorimeter
(HORIBA Jobin Yvon, Edison, New Jersey) was used to excite the sample at 780 nm, and the
resulting emission spectrum (see FIGURE 5-5) was integrated from 450 nm to 685 nm
(corresponding to the longest emission wavelength collected during TPM imaging). The mean
area under the curve for SRB was divided by the mean area under the curve for SRG, yielding a
value of 1.92 ± 0.17 (mean ± SD).
* Interestingly, in aqueous solutions, SRG fluoresces more brightly than SRB (data not shown).
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AFIGURE 5-4: Intercellular penetration profiles of SRB (A) and of SRG (B). SRB and SRG were
applied to pig skin at 1 mM concentration. The presence of SRB and of SRG is indicated by the
red color. Image depth, 2 urm below the skin surface. Bar = 20 rm.
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FIGURE 5-5: Emission spectra of SRG and SRB in PBS-saturated octanol. The labels 1 - 3
indicate different samples. Solutions were excited at 780 nm. As can be seen, SRB is nearly
twice as bright as SRG in a non-polar environment.
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5.2.9 STATISTICAL ANALYSIS
Two-sample, two-tailed t-tests assuming unequal variances were used to compare skin
current ERs, fluorescence intensities, and oil/water interfacial tension values. In all analyses, p
values <0.05 were considered to be statistically significant.
5.3 RESULTS AND DISCUSSION
5.3.1 RANKING OF THE FPE CANDIDATES AS SKIN PENETRATION ENHANCERS
The potency of the FPE candidates as skin penetration enhancers was quantified by the
skin current enhancement ratio (ER). Skin electrical current is a sensitive quantitative indicator
of skin permeability [58,63]. The results of these experiments are summarized in FIGURE 5-6.
Eight of the twelve FPE candidates (BODIPY1, AO, SRG, RB, R6G, DCDHF, MO, and
BODIPY2) exhibited ERs significantly different from that of the negative control; therefore, they
are transdermal FPEs. In fact, the best candidates exhibited ERs similar to that of SLS, a well-
known potent penetration enhancer (positive control). These results demonstrate that the
presence of a fluorescent group in the structure does not prevent molecules from acting as potent
penetration enhancers.
126
SIS
BODIPY1 5E5ERTI *
AO
SRG J!,EEsiH--
RB
R?6G*
DCDHIF Ei25%91-
MO
BODIPY2 S~f Ni-I
TAMRA
FLUOR
SRB 1:7
40% Ethanol
0 2 4 6 8 10 12
Skin Current ER
FIGURE 5-6: Skin current enhancement ratios (ERs) exhibited by the FPE candidates considered.
SLS served as a positive control. Solute concentrations were 1 mM (except for DCDHF, 0.02
mM). Error bars indicate 95% confidence intervals. * indicates significant difference compared
to 40% ethanol (negative control). n = 40 for 40% ethanol; n = 9 - 13 for all others.
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Next, several comments can be made regarding the correlation of the rank of the FPE
candidates with their chemical structure. First, the rhodamine candidates (molecules 7 - 12 in
TABLE 5-1) are generally bulkier than the candidates with long, saturated carbon chains
(molecules 1 - 5 in TABLE 5-1). Based on this comparison, one would intuitively expect the
candidates with long carbon chains to better penetrate into skin and perturb the skin lipid
bilayers. Nevertheless, the ERs of these candidates and of the rhodamine candidates are evenly
interspersed between the ERs of the positive and negative controls. In fact, some candidates from
both groups exhibited ERs close to that of the positive control. These results are in agreement
with previous findings. First, recall that many drugs that are successfully administered via a
transdermal patch are hormones with multiple rings [44], similar to the rhodamine candidates.
Second, Mitragotri and co-workers previously designed over 300 mutated chemical skin
penetration enhancers based on potency and safety [106]. Their 6 best compounds were ones
with either long, saturated carbon chains or with multiple rings.
Second, it is reasonable that BODIPY1 exhibited a greater ER than BODIPY2. While
both molecules have long hydrocarbon chains, the fluorophore in BODIPY1 is positioned in the
middle of the chain, and the fluorophore in BODIPY2 is positioned at the end of the chain.
Penetration enhancers with long hydrocarbon chains can readily intercalate into the structured
lipid bilayers of the stratum corneum and disrupt the lipid packing, thereby increasing lipid
fluidity and reducing the skin diffusion barrier [124]. However, it is hypothesized that the
location of the fluorophore at the end of the hydrocarbon chain (as in BODIPY2) would hinder
the chain from intercalating into lipid bilayers. It has previously been shown that the depth of
penetration into a lipid membrane depends on the steric bulk of the intercalant [125]. Since
BODIPY1 is a better penetration enhancer than BODIPY2, this result suggests that the ideal
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location for the fluorophore is adjacent to the head group. It would be interesting to evaluate
such a molecule, which is speculated to result in a more potent FPE. Note that BODIPY is a
popular fluorophore because its robust fluorescence properties are highly favorable for many
imaging applications [126]. Therefore, a modified BODIPY-based FPE has the potential to be
utilized in many types of imaging studies.
Third, it is interesting that DCDHF, while applied to skin at 1/50* of the concentration
of the other candidates, still exhibited a significantly large ER. This indicates that this structure
has great potential as a FPE. There are three distinguishing features of DCDHF that may
contribute to its significant penetration enhancer activity: (i) nitrile head groups, which have
been linked with skin irritation and toxicity [127] (and these properties are often exhibited by
potent penetration enhancers [106]), (ii) a 12-carbon tail, which has previously been shown to be
the optimal tail length for skin penetration enhancers [112], and (iii) a compact fluorophore with
a small number of rings, located adjacent to the nitrile head groups. However, in spite of the fact
that DCDHF exhibited potency at a low concentration, it is limited by its poor water solubility.
This structure, which has been shown to be readily derivatized [128,129], may be improved by
adding a water-soluble group such as sulfonic acid (e.g. fluorophore 21 in [129], shown in
FIGuRE 5-7).
Fourth, in spite of the fact that SRG and SRB have similar chemical structures, SRG is a
significant FPE, while SRB is not. In Section 5.3.2.2, TPM was utilized to visualize the skin
penetration profiles of SRG and SRB in order to independently substantiate these interesting
results with data from image analyses. As discussed in Section 5.2.1, SRG was selected as a FPE
candidate because it is smaller than SRB. However, FIGURE 5-8 shows that over the range of
molecular weights studied (327 - 581 Daltons), there is no correlation between molecular weight
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and potency as a transdermal FPE. Subsequently, SRG was hypothesized to be more amphiphilic
than SRB. A basic feature of amphiphiles is that they can reduce surface or interfacial tensions.
Therefore, to compare the amphiphilicity of SRG and SRB, their reduction of the interfacial
tension between oil (decane) and water was measured. FIGURE 5-9 shows that SRG is
significantly more effective than SRB at lowering the oil/water interfacial tension. This indicates
that SRG is indeed more amphiphilic than SRB. One difference in their chemical structures is
that the 3-ring xanthene structure of SRB has a delocalized charge of +1 due to resonance; the
xanthene structure of SRG is not necessarily protonated. Therefore, the structure of SRG allows
for a better distribution of charges and a clearer distinction between head and tail regions. In
addition, the +1 charge of the xanthene structure of SRB may result in different interactions with
the negatively-charged skin, or may result in intramolecular interactions with the sulfonate-
containing pendant group. It would be interesting to investigate the structure-activity differences
(i.e. the relationship between the chemical structure and the penetration enhancer activity
[123,130,131]) between SRG and SRB in future studies.
NC NC
H3C(H2C)10  C
Ho CN
HOL 1
110
FIGuRE 5-7: DCDHF functionalized with sulfonic acid to impart water solubility (molecule 21 in
[129]).
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FIGURE 5-8: Skin current enhancement ratio vs. molecular weight of the FPE candidates
considered. The numbers adjacent to the blue diamonds correspond to the various FPEs listed in
TABLE 5-1. Note that DCDHF is excluded from this figure because the skin treatment conditions
differed from that of the other candidates.
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FIGURE 5-9: Lowering of oil/water interfacial tension
Error bars indicate 95% confidence intervals. n = 3.
(Ay). SLS served as a positive control.
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5.3.2 TPM CASE STUDIES: VISUALIZATION OF FPE PENETRATION INTO SKIN
In the previous section, several FPE candidates were demonstrated to be skin penetration
enhancers. These FPEs now enable the use of a multitude of fluorescence techniques to
investigate FPE-enhanced transdermal applications. As an example, two-photon fluorescence
microscopy (TPM) was used to demonstrate several applications where the direct visualization
of FPEs can provide new physical insight.
5.3.2.1 VISUALIZATION OF THE EFFECT OF SKIN TREATMENTS ON SRG
PENETRATION
Representative TPM images of SRG-, SRG/glycerol-, and SRG/US-treated skin samples
are shown in FIGURE 5-10. Recall that glycerol and US treatments are well-established skin
treatments that are utilized for decreasing and increasing skin penetration, respectively. First, the
effect of glycerol on SRG penetration into skin is discussed. In SRG-treated skin, the SRG
remained localized within the lipid bilayers surrounding the corneocytes (see FIGURE 5-10A);
this localization was observed uniformly throughout the skin sample. With the addition of
glycerol, the SRG penetration pattern remained the same (see FIGURE 5-10B), however, SRG
fluorescence intensities were smaller. The images were analyzed to determine the average SRG
intensity profiles in the presence and in the absence of glycerol. These data, presented in FIGURE
5-11, show that glycerol significantly mitigated the penetration of SRG into skin (by 20%),
which is consistent with the well-documented anti-irritant properties of glycerol
[109,110,120,132]. Note that it was verified that glycerol does not directly affect the
fluorescence intensity of SRG (i.e. the SRG donor solution fluorescence intensities with and
without 10% glycerol were the same; data not shown).
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FIGURE 5-10: SRG penetration patterns within SRG-treated, SRG/glycerol-treated, and SRG/US-
treated pig skin. The presence of SRG is indicated by the red color. (A) Representative image of
SRG-treated skin (image depth, 2 pm below the skin surface). (B) Representative image of
SRG/glycerol-treated skin (depth, 2 pm). (C, D) Selected regions of interest within the stratum
corneum of SRG/US-treated skin (depth, 2 gm). (E) Selected region of interest within the
epidermis of SRG/US-treated skin (depth, 34 pm). Bar = 20 pm.
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FIGURE 5-11: Average SRG fluorescence intensity as a function of skin depth, in the presence
and in the absence of 10% glycerol. Fluorescence intensities are significantly different at all skin
depths. Error bars indicate 95% confidence intervals. n = 18 sites for SRG; n = 12 sites for
SRG/glycerol.
Next, the effect of US on SRG penetration into skin is discussed. US significantly affects
the SRG penetration pattern. FIGURE 5-10C and FIGURE 5-10D show that US assists the
penetration of SRG into skin via irregular, transcellular pathways. In fact, no patterns resembling
intercellular routes (as seen in FIGURE 5-10A) were observed in SRG/US-treated skin, which
suggests that transcellular pathways are dominant in US-treated skin. Furthermore, SRG
penetration was only observed in discrete regions that were heterogeneously distributed across
the treated skin area, corresponding to localized transport regions (LTRs) that have been well
documented within US-treated skin [27,30] (see Chapter 1, Section 1.4.3). LTRs are regions
where US-induced cavitation microjets drive SRG into the skin [133]. Finally, with the
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assistance of US, SRG penetrated into the epidermis in localized regions in significant amounts
(see FIGURE 5-10E), whereas without US, SRG did not significantly penetrate into the epidermis
(not shown). Note that in FIGURE 5-10E, the 5-jm circular regions where SRG did not penetrate
correspond to the epidermal cell nuclei.
This TPM application demonstrates that by using a FPE, one can directly visualize how
changes to a topical formulation or skin treatment affect the penetration and spatial distribution
of the FPE within skin. FPEs can now be utilized to aid in designing safe and effective skin
treatments and topical formulations, which often contain penetration enhancers.
5.3.2.2 VISUAL COMPARISON OF THE PENETRATION PROFILES OF SRG AND SRB
SRB- and SRG-treated skin samples were imaged using TPM. In both cases, the
fluorescence remained localized within the lipid bilayers surrounding the corneocytes (see
FIGURE 5-4). The images were analyzed to determine the average SRB and SRG intensity
profiles. FIGURE 5-12 shows that SRB did not penetrate as readily into the skin as SRG, which is
consistent with the finding that SRG is a significant FPE while SRB is not (see Section 5.3.1).
With higher resolution fluorescence techniques (such as single-molecule fluorescence techniques
[108]), one may be able to elucidate the differences in mechanisms of skin penetration for
significant and insignificant penetration enhancers, which would aid in designing potent, yet
safe, penetration enhancers for drug delivery.
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FIGURE 5-12: Average SRG and SRB fluorescence intensity as a function of skin depth.
Fluorescence intensities are significantly different at all skin depths. Error bars indicate 95%
confidence intervals. n = 18 sites for both SRG and SRB. SRB data were normalized as
described in Section 5.2.8.3.
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5.3.2.3 DUAL-CHANNEL IMAGING OF SRG AND SKIN AUTOFLUORESCENCE
Skin autofluorescence stems from intrinsic skin components, including collagen, elastin,
aromatic amino acids, and cofactors [134]. These components reside in the lipid bilayers; by
imaging skin autofluorescence, one can delineate the corneocyte-lipid bilayer interface.
Therefore, by simultaneously imaging the probe spatial distribution and the skin
autofluorescence, one can identify changes in probe partitioning between the corneocytes and the
lipid bilayers and/or probe-induced structural changes in the skin structure [111,134].
This is demonstrated using dual-channel TPM to image SRG-treated skin (see FIGURE
5-13). In the green channel, the skin autofluorescence is generally limited to the intercellular
regions surrounding the corneocytes, thereby delineating the skin structure. The corneocyte
dimensions are approximately 20 tim, which is consistent with previous reports [7]. In the red
channel, it is clear that SRG is not always present throughout the entire intercellular space;
instead, there is an apparent preferential localization within a 1 -p m thick region at the
corneocyte-lipid interface (see arrows in FIGURE 5-13). This region may include the 15-nm
cornified cell envelope, which is composed of a mixture of cross-linked protein filaments and
lipid molecules [7]. This localization suggests that SRG is amphiphilic, which was evaluated in
Section 5.3.1. Other higher resolution fluorescence techniques (such as single-molecule
fluorescence techniques [108]) can be used to investigate this localization further, which may
contribute new physical insights on the interactions between FPEs and the skin.
Note that in FIGURE 5-4 and FIGURE 5-10, SRG was applied to the skin at 1 mM
concentration, while in FIGURE 5-13, SRG was applied at 3.6 gM concentration. In FIGURE 5-4
and FIGURE 5-10, SRG is present throughout the lipid bilayers likely because the corneocyte-
lipid interfacial regions are saturated.
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FIGURE 5-13: Representative dual-channel images of SRG and human skin autofluorescence at
the skin surface. Left column, SRG channel (the presence of SRG is indicated by the red color);
right column, skin autofluorescence channel (the presence of skin fluorophores is indicated by
the green color). Arrows point to regions where SRG is only localized within the corneocyte-
lipid interface (i.e. SRG is not present throughout the entire intercellular region). Bar = 20 gm.
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5.4 CONCLUSIONS
In this chapter, eight FPEs have been identified for transdermal applications, with the
best FPEs exhibiting skin current ERs similar to that of SLS, a well-known potent penetration
enhancer. TPM was utilized to directly and non-invasively visualize FPEs within skin for the
first time, including: (i) visualizing glycerol-mitigated and ultrasound-enhanced FPE skin
penetration, (ii) visually confirming that SRB does not penetrate as readily into the skin as SRG,
which is consistent with the finding that SRG is a significant FPE while SRB is not, and (iii)
using dual-channel TPM to demonstrate the visualization of a FPE with respect to the skin
structure. These demonstrations reinforce the novel strategy of combining FPEs with well-
established fluorescence techniques to elucidate mechanisms of penetration enhancement and
skin irritation. FPEs will allow a multitude of fluorescence techniques to be utilized in order to
directly visualize penetration-enhanced transdermal drug delivery. With further studies, more
potent transdermal FPEs may be designed. New physical insights obtained using this approach
will aid in designing effective penetration enhancers for transdermal drug delivery applications.
The exciting results presented in this chapter lay the foundation for the future work proposed in
the next chapter.
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CHAPTER 6
SUMMARY OF CONTRIBUTIONS, IMPACT, AND RECOMMENDATIONS
The unifying theme throughout this thesis has been the development of novel
experimental strategies and analyses that can be utilized in in vitro investigations of passive and
ultrasound-enhanced transdermal drug delivery. This thesis is concluded with a summary of each
chapter's contributions and impact. As discussed below, the experimental strategies presented in
this thesis open doors for investigations in several transdermal fields, including evaluating
nanoparticle skin toxicity, designing nanoparticle drug delivery carriers, evaluating ultrasound-
assisted transdermal vaccination, elucidating mechanisms of chemical penetration enhancer-
induced skin irritation, designing topical formulations with penetration enhancers, and
elucidating ultrasound and penetration enhancer synergism in enhancing skin permeability.
Finally, detailed recommendations are offered for future studies.
6.1 THESIS CONTRIBUTIONS AND IMPACT
6.1.1 CHAPTER 3
Chapter 3 demonstrated that pig split-thickness skin (STS) is a suitable in vitro skin
model for investigating the US/SLS-enhanced delivery of hydrophilic permeants. To attain this
goal, first, a method of data analysis was developed to evaluate the rate of permeant
accumulation in the receiver chamber of a Franz diffusion cell to determine if permeant diffusion
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across skin occurred under steady-state, sink conditions. A second method of data analysis was
developed to apply the aqueous porous pathway model (APPM) to compare log permeability -
log resistivity data sets from various skin models. These methods were applied to three human
skin models and two pig skin models of varying thicknesses. Skin thickness was determined to
affect the response of the human skin models to US/SLS treatment, while the difference in
thickness did not affect the response of the two pig skin models to US/SLS treatment. This
difference in results for pig and human skin models was attributed to intrinsic differences within
the skin models. Finally, to motivate the use of STS in future studies, it was demonstrated that
the dermis acts as a barrier to two model, hydrophilic macromolecules (gold nanoparticles and
quantum dots).
After the completion of this study, another study was designed based on the two methods
of data analysis developed in Chapter 3. Specifically, I assisted in designing and conducting
another study in which the APPM-based analysis was applied to compare the effect of SLS on
US-induced skin structural perturbation within full-thickness skin and STS models [97]. In this
study, the structural parameters of skin treated with US/SLS and US were compared in order to
quantify the effect of SLS on skin structural perturbation within US-treated skin [97].
In addition, after demonstrating that pig STS is a convenient skin model for evaluating
the US/SLS-enhanced delivery of macromolecules, the pig STS model was used in Chapter 4 for
the US/SLS-enhanced delivery of quantum dots. STS has minimal variation in dermal thickness;
therefore, the use of STS in this study reduced the variability in: (i) the amount of quantum dots
quantified in the dermis by elemental analysis (see Chapter 4, Section 4.2.6.1), and (ii) the
compression of the skin when it is mounted into an imaging chamber for confocal microscopy
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analysis (see Chapter 4, Section 4.2.6.2), which affects the observed quantum dot penetration
depth.
Finally, the STS model will be useful in future studies of the delivery of permeants such
as vaccines into, rather than across, US/SLS-treated skin. Specifically, when the drug delivery
targets are the Langerhans cells or the blood capillaries at the epidermis-dermis junction [135], it
will be desirable to conduct in vitro US/SLS-enhanced transdermal diffusion experiments using
STS models, in which much of the dermis is removed in order to more accurately represent the in
vivo transdermal diffusion barrier between the skin surface and the desired skin component.
6.1.2 CHAPTER 4
In Chapter 4, the US/SLS treatment was applied to enhance the transdermal delivery of
nanoparticles, which was evaluated both quantitatively and qualitatively. Using elemental
analysis, quantum dot (QD) penetration into the dermis of untreated skin was demonstrated
quantitatively for the first time.* In addition, the US/SLS treatment was shown to significantly
enhance QD transdermal penetration by 500 - 1300%. Qualitatively, a novel application of
confocal microscopy was developed to visualize the penetration of QDs into the dermis. Using
confocal microscopy, QDs were observed to penetrate into skin in heterogeneous patterns, thus
explaining why the literature contains conflicting reports regarding the ability of nanoparticles to
penetrate skin. Finally, it was demonstrated that a more highly cationic surface charge does not
necessarily result in greater nanoparticle skin penetration.
Future studies should be conducted to determine the optimum cationic surface charge for
nanoparticle skin penetration. Nanoparticle surface charge can potentially be designed to target
* Note that QD penetration into the dermis of US/SLS-treated skin was quantified for the first time in Chapter 3,
where QDs were used as a model macromolecule to demonstrate that the dermis acts as a barrier to macromolecules.
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particular entities within the skin at specific penetration depths. Subsequently, US/SLS treatment
followed by the passive application of cationic nanoparticle carriers can be a good strategy, not
only for transdermal drug delivery, but also for topical drug delivery and for transcutaneous
immunization. The US/SLS-enhanced delivery of a nanoparticle carrier is particularly relevant
for transcutaneous immunization. First, a nanoparticle carrier can enhance the delivery of a
vaccine to the dendritic cells within skin, and furthermore, the carrier can be targeted to enhance
the specific uptake of the vaccine by the dendritic cells [91]. Second, the US/SLS treatment can
enhance the immune response induced by simple, naked vaccine application by enhancing the
penetration of the vaccine and by acting as an adjuvant [47,48,136]. Therefore, the combined
application of cationic nanoparticle carriers to US/SLS-treated skin is proposed as an interesting
and valuable tool for further developing transcutaneous immunization.
In addition, the combination of quantitative and qualitative methods to evaluate
nanoparticle penetration into skin can be implemented in other transdermal applications besides
drug delivery, e.g. to address the hypothesis that assessment of nanoparticle skin penetration
depends on the skin model, as well as to address conflicting reports regarding nanoparticle skin
toxicity (see Chapter 4, Section 4.4.1 for a detailed discussion).
6.1.3 CHAPTER 5
In Chapter 5, a novel concept was proposed to use fluorescent chemical penetration
enhancers (FPEs) in order to take advantage of a multitude of well-established fluorescence
technologies and gain new insights into the behavior of penetration enhancers within skin.
Twelve FPE candidates were selected, and eight were demonstrated to be significant transdermal
FPEs, where the best FPEs found compared well to sodium lauryl sulfate, a well-known potent
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skin penetration enhancer. Based on the ranking of the FPEs, design principles for FPEs were
presented. Two-photon fluorescence microscopy was used to directly and non-invasively
visualize the penetration patterns of FPEs within skin for the first time.
In future studies, FPEs can be combined with advanced fluorescence technologies to shed
light on the behavior of penetration enhancers within biological membranes and elucidate the
mechanisms involved in penetration enhancement and membrane irritation. The FPE candidates
identified in Chapter 5 can also be evaluated using lipid-based membranes associated with other
drug delivery routes (e.g. corneal, buccal, and intestinal). Certain skin penetration enhancers
have previously been shown to be effective in other types of lipid-based membranes, including
the buccal mucosa [104].
Transdermal FPEs can also be utilized to aid in designing safe and effective skin
treatments and topical formulations, e.g. in the cosmetics and personal care industries. Many
transdermal products contain penetration enhancers. By adding a FPE to a series of formulations,
one can visually compare how various formulations affect the penetration and spatial distribution
of the FPE within skin, as demonstrated in Section 5.3.2.1. In addition, by using a red-emitting
FPE and dual-channel imaging as demonstrated in Section 5.3.2.3, one can simultaneously
visualize the effect of the FPE on the integrity of the skin structure.
Finally, the successful transdermal FPEs identified in Chapter 5 can serve as the basis for
designing a homologous series of FPEs that vary in one property (e.g., head group, charge, and
tail length) in order to visually investigate the effect of this property in transdermal applications.
For example, acridine orange 10-nonyl bromide (AO) exhibited a significant skin current
enhancement ratio (see Chapter 5, Section 5.3.1). Since the synthesis of acridine orange
derivatives with various tail lengths is relatively straightforward (from acridine orange
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hydrochloride hydrate and alkyl bromides [137]), AO has inspired a homologous series of FPEs
for visually investigating the effect of tail length on skin penetration and irritation. I am currently
assisting with evaluating this series of acridine orange derivatives (with hydrocarbon tail lengths
of 8 - 16 carbons) for potency as transdermal FPEs and for combination with US as synergistic
penetration enhancers, and I am utilizing two-photon fluorescence microscopy to investigate the
effect of the tail length on the spatial distribution of the FPE within untreated and US-treated
skin. Other specific examples of designing FPE candidates based on the ones evaluated in
Chapter 5 are discussed in Section 6.2.3.
6.2 DETAILED RECOMMENDATIONS FOR FUTURE STUDIES
6.2.1 EVALUATING OTHER SPLIT-THICKNESS SKIN MODELS
The results of Chapter 3 strongly suggest the use of STS to investigate the US/SLS-
enhanced delivery of hydrophilic macromolecules. If one wishes to obtain US/SLS-enhanced
STS permeabilities that are not significantly different than those obtained using full-thickness
skin (FTS), the findings suggest the use of 700-pm thick pig STS as an alternative skin model to
pig FTS. Additional experiments would be needed to investigate the effects of US/SLS on pig
STS models thinner than 700 pm. Pig STS models thinner than 450 pm have already been
determined to be unsuitable for US/SLS studies (see Chapter 3, Section 3.6). Therefore,
additional studies should investigate intermediate thicknesses between 700 pm and 450 pm in
order to determine the threshold thickness for which pig STS is suitable for US/SLS studies.
Regarding human STS, since 700-pm thick human skin and human FTS respond differently to
the US/SLS treatment described in Chapter 3, other US/SLS conditions (e.g. milder treatments at
lower US intensities) or human STS models thicker than 700 pm may be evaluated. Then, as
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described in Sections 6.1.1 and 6.1.2, validated STS models can be used to study the US/SLS-
enhanced delivery of nanoparticle-encapsulated vaccines into skin.
6.2.2 EVALUATING THE SPLIT-THICKNESS SKIN MODEL FOR THE US/SLS-
ENHANCED TRANSDERMAL DELIVERY OF HYDROPHOBIC PERMEANTS
This proposed study is a natural continuation of the study presented in Chapter 3, to
compare the US/SLS-enhanced delivery of hydrophobic permeants through FTS and STS. For
hydrophilic permeants, FTS and STS were compared using analyses based on the aqueous
porous pathway model for hydrophilic permeants. At this time, there is no analogous theoretical
transport model that can be readily applied to compare the pathways that hydrophobic permeants
utilize to permeate US/SLS-treated skin. While there are several structure-based models for the
transport of hydrophobic permeants through the stratum corneum (e.g. [138]), the application of
these models requires isolating the stratum corneum as an intact membrane for permeation
experiments, which is not possible for US/SLS-treated skin because US/SLS disrupts the stratum
corneum. Therefore, I suggest the use of a non-invasive, fluorescence-based quantitative analysis
as an alternative method to compare the hydrophobic transport pathways through the stratum
corneum of US/SLS-treated pig FTS and STS. Note that this method assumes that the stratum
corneum remains a significant diffusion barrier to hydrophobic permeants after US/SLS
treatment. This has been confirmed in separate experiments (see Appendix, Section 6.3).
With the above motivation in mind, confocal or two-photon fluorescence microscopy can
be used to visualize the hydrophobic transport pathways through the stratum corneum of
US/SLS-treated pig FTS and STS. A hydrophobic fluorescent dye is necessary to probe the
hydrophobic transport pathways, and rhodamine B hexyl ester (RBHE) has previously been used
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in transdermal studies for this purpose (e.g. [54,111,121,139,140]). However, considering the
recent publication by Polat et al. which showed that sulforhodamine B (SRB) (a rhodamine dye
that has often been used as a model hydrophilic probe) is actually amphiphilic [114], it would be
prudent to verify that RBHE does not exhibit amphiphilic properties. In addition, in light of the
results presented in Chapter 5, which showed that some rhodamine dyes can act as transdermal
penetration enhancers, it would also be prudent to verify that RBHE does not act as a penetration
enhancer. Note that while SRB was shown to be an insignificant passive penetration enhancer
(without US), Polat et aL. showed that SRB and US exhibit synergism as penetration enhancers
[114]. If one includes a fluorescent dye in the coupling medium during US treatment, which is
often done to visualize the US/SLS-enhanced transport pathways or regions within skin [27,28],
then the determination that the fluorescent dye is not a passive penetration enhancer would be
insufficient; one would also need to determine whether the dye exhibits synergism with US in
enhancing skin penetration. These steps must be taken before using RBHE (or any other dye) as
a model hydrophobic probe in future studies. Otherwise, if the probe is not "inert", then the
analysis of the results of this proposed study would not be straightforward.
Upon selecting an appropriate hydrophobic probe to visualize the hydrophobic
transdermal transport pathways, quantitative analyses which have previously been described
[111] can be applied to the confocal or two-photon microscopy images to compare the following
properties of hydrophobic probe penetration into US/SLS-treated pig FTS and STS: (i) the
vehicle-to-skin partition coefficient, (ii) the concentration gradient, and (iii) the effective
diffusion path length. In this manner, the hydrophobic transport pathways between FTS and STS
can be non-invasively, yet quantitatively, compared to determine if STS is a suitable alternative
skin model for the US/SLS-enhanced delivery of hydrophobic permeants.
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6.2.3 EVALUATING ADDITIONAL FPE CANDIDATES
After successfully identifying transdermal FPEs in Chapter 5, these structures can serve
as the basis for selecting or synthesizing more FPE candidates. Below, several interesting
molecules are listed. The chemical structures of these molecules are provided in FIGURE 6-1.
" DCDHF exhibited great potential as a FPE for transdermal applications, but it is limited by
its poor water solubility. This structure, which has been shown to be readily derivatized
[128,129], may be improved by adding a water-soluble group such as sulfonic acid (e.g.
fluorophore 21 in [129]; see FIGURE 6-1, molecule 1).
" The BODIPY group is a desirable fluorophore because its robust fluorescence properties are
highly favorable for many imaging techniques [126]. Given that BODIPY1 is a better
chemical enhancer than BODIPY2, it would be interesting to evaluate a compound such as
molecule 2, shown in FIGURE 6-1. In molecule 2, the BODIPY group is positioned between
the head and tail groups, which is hypothesized to result in a more potent FPE.
" It has previously been shown that chemical penetration enhancement depends strongly upon
the head group [112]. Since BODIPYl and BODIPY2 with carboxylic acid head groups are
transdermal FPEs, it would be interesting to evaluate a BODIPY molecule with a sulfate
head (see FIGURE 6-1, molecule 3). This is hypothesized to result in a more potent FPE
because the sulfate head group likely contributes to the potency of SLS as a penetration
enhancer. Molecule 3 has previously been available through Invitrogen (Carlsbad, CA) as
catalog number D3862, however it is currently a discontinued product. Nevertheless, it could
be obtained from Invitrogen as a custom synthesis.
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FIGURE 6-1: Additional molecules that may be considered for evaluation as fluorescent
penetration enhancers.
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* Another discontinued Invitrogen product is H22730 (see FIGuRE 6-1, molecule 4), which was
marketed as an amphiphilic coumarin fluorescent dye. This molecule would be interesting to
evaluate as a FPE because it has a low molecular weight of 400 Daltons, a compact
fluorophore, and a long hydrocarbon tail. This could be obtained from Invitrogen as a custom
synthesis. It would also be interesting to synthesize a derivative with a tail length of twelve
carbons, which has previously been shown to be the optimal tail length for chemical
penetration enhancement [112].
* Molecules 5 and 6 were synthesized by Brett VanVeller in Professor Timothy Swager's
laboratory in the MIT Department of Chemistry. These molecules have long hydrocarbon
tails and compact fluorophores located adjacent to the sulfonate head groups. They were
synthesized by reacting 4-chloro-7-sulfobenzofurazan ammonium salt (Sigma C 1154) with
nonylamine and with dodecylamine, respectively [141]. Prior to purification, molecule 5
exhibited a statistically significant skin current enhancement ratio of 5.9 ± 1.8 (mean ± 95%
confidence interval; n = 10) in preliminary experiments conducted as described in Chapter 5,
Section 5.2.6. It is hypothesized that molecule 6 would exhibit a greater enhancement ratio
than molecule 5 because a 12-carbon tail length has previously been shown to be optimal for
penetration enhancement [112]. It would be interesting to rigorously evaluate these
molecules after purification.
* Molecule 7 was synthesized by Amanda Engler in Professor Paula Hammond's laboratory in
the MIT Department of Chemical Engineering. It was synthesized by reacting 5/6-carboxy-
tetramethyl-rhodamine succinimidyl ester (Thermo Scientific Pierce 46406) with
heptylamine to form the amide. The motivation for synthesizing this molecule is as follows.
Several rhodamine derivates were determined to be transdermal FPEs in Chapter 5, in spite
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of the fact that they do not have long hydrocarbon tail groups. Therefore, it was hypothesized
that the addition of a hydrocarbon tail to a rhodamine derivative would result in a potent
penetration enhancer. Prior to purification, molecule 7 (which is a mixture of isomers)
exhibited a statistically significant skin current enhancement ratio of 6.8 ± 3.1 (mean ± 95%
confidence interval; n = 9) in preliminary experiments conducted as described in Chapter 5,
Section 5.2.6. It would be interesting to rigorously evaluate these molecules after the
separation of isomers and the subsequent purification.
* Molecule 7 was synthesized using a common synthetic route for amide formation, which can
be used to add hydrocarbon tails of various lengths to other fluorophores. For example,
molecules 8 and 9 can be synthesized by reacting heptylamine with Alexa Fluor 488
carboxylic acid succinimidyl ester (Invitrogen A20100) and Alexa Fluor 350 carboxylic acid
succinimidyl ester (Invitrogen A10168), respectively. Molecule 8 is interesting because it
contains two sulfonate groups, which would impart significant water solubility to the
molecule. Molecule 9 is interesting because it has a compact fluorophore located adjacent to
several water-soluble functional groups. Note that the tail length of these molecules could be
varied by using amines with various hydrocarbon chain lengths in the synthesis.
* Yet another rhodamine derivative that contains a hydrocarbon chain is rhodamine B hexyl
ester (RBHE), which is commercially available (see FIGuRE 6-1, molecule 10). However,
regarding molecules such as 7 and 10: Note that Polat et al. showed that sulforhodamine B
(SRB) has defined polar ("head") and non-polar ("tail") regions. The division between the
head and the tail can be made by laterally bisecting the 3-ring xanthene structure, with the
section of SRB containing the sulfonate groups (see Chapter 5, FIGURE 5-1) comprising the
head [114]. Assuming that this division is consistent for all rhodamine derivatives, then in
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these molecules, the hydrocarbon chain branching off the head group may be considered to
be a second tail group. Therefore, the analysis of the structure-activity relationship of these
molecules may not be straightforward.
6.2.4 INVESTIGATING THE ROLE OF AMPHIPHILICITY IN THE STRUCTURE-ACTIVITY
RELATIONSHIP OF FPEs
Since amphiphilicity was the general basis for choosing the FPE candidates selected in
Chapter 5, it would be interesting to rank the FPEs according to amphiphilicity and to determine
if there is a correlation between amphiphilicity and potency. Regarding amphiphilicity, note that
the oil/water interfacial tension measurements described in Chapter 5 cannot be applied to all of
the FPE candidates because not all of them are soluble in either decane or water. Therefore, in
order to rank the FPEs according to amphiphilicity, another oil/water system must be chosen, or
another metric must be used for this study. Regarding potency, one must obtain statistically
significant differences among the skin current enhancement ratios (ERs) exhibited by the FPEs
in order to rigorously determine if there is a correlation between amphiphilicity and potency. In
Chapter 5, the experiment for evaluating the potency of FPE candidates was designed to be
applicable to 11 of the 12 selected FPE candidates (measurement of the ER exhibited after a 24-
hour application of the FPE candidate to the skin at 1 mM in 40% ethanol). This design resulted
in a relatively small difference in the ERs exhibited by the positive and negative controls (see
Chapter 5, FIGuRE 5-6), making it difficult to obtain a statistically significant ranking among the
FPE candidates. In order to obtain a statistically significant ranking, either many replicates are
required in order to increase the confidence level in the data or the experimental conditions need
to be modified.
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To overcome the above challenges, this study could be conducted for a subset of FPEs
that are water soluble. As a result, first, surface tension measurements at an air-water interface
could be used to rank the FPEs by amphiphilicity. Second, this would allow a larger
concentration of solute to be used when evaluating the potency of the FPE (up to the water
solubility limit of the FPEs). In turn, this would increase the difference in ERs exhibited by the
positive and negative controls, thereby making it easier to obtain statistically significant
differences in ERs among the FPEs. Note that by using only water-soluble FPEs, ethanol would
not be needed as a co-solvent. The removal of ethanol from the system would also help in
obtaining a larger difference in the ERs exhibited by the positive and negative controls because
the FPEs would not need to compete with ethanol as a penetration enhancer.
At this time, only a few of the FPEs identified in Chapter 5 are significantly water soluble
for this proposed study. Several molecules identified in Section 6.2.3 should be evaluated prior
to this study in order to increase the number of water-soluble FPEs. Then, if there is a strong
correlation between amphiphilicity and potency of water-soluble FPEs, the visualization of the
FPEs within skin would assist in elucidating the mechanism of penetration enhancement by
amphiphiles. In addition, amphiphilicity may be included as a new parameter in structure-activity
relationships for penetration enhancers and in designing potent penetration enhancers.
Furthermore, amphiphilic fluorescent molecules, or fluorosurfactants, would be useful in many
other fields, e.g. cosmetic and pharmaceutical topical formulation design, surfactant-induced skin
irritation, and surfactant-enhanced transdermal drug delivery. Specifically, fluorosurfactants that
can penetrate into skin can be utilized to visualize how mixing surfactants can be used to
decrease skin penetration and irritation. One can visualize how the distribution, composition, and
concentration of the fluorescent surfactant in the skin are changed by: (i) mixing with traditional
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surfactants, (ii) adding a humectant, and (iii) adding a polymer. The Blankschtein Lab has
previously shown that these strategies can be used to modulate the skin penetration of traditional
surfactants [110,120,132,142,143]. Generalizing these studies using a fluorosurfactant would be
very exciting, and would be of great interest to the cosmetics and personal care products
industries.
6.3 APPENDIX: EVALUATION OF THE STRATUM CoRNEuM's DIFFUSION BARRIER
TO HYDROPHOBIC PERMEANTS AFTER US/SLS TREATMENT
6.3.1 MATERIALS AND METHODS
6.3.1.1 SKIN PREPARATION
700-pm thick pig split-thickness skin samples were prepared as described in Chapter 3,
Section 3.2.2. Next, US/SLS treatment was applied to the skin samples as described in Chapter 4,
Section 4.2.4. Samples prepared using this method are referred to hereafter as "intact" skin.
Subsequently, "tape-stripped" skin was prepared from intact skin by repeated tape stripping,
using up to 35 strips of Scotch* book tape (3M, St. Paul, Minnesota) until the stratum corneum
was removed. This endpoint was achieved when the epidermal surface glistened and the tape
strips no longer removed any skin fragments. Note that tape-stripping is a commonly reported
method for removing the stratum corneum.
6.3.1.2 NAPHTHOL PERMEATION THROUGH SKIN
Naphthol was selected as a model hydrophobic permeant because it has previously been
used for transdermal diffusion experiments [138,144,145]. 1-'4C-labeled naphthol-a in ethanol
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(55 mCi/mmol) was obtained from American Radiolabeled Chemicals (St. Louis, Missouri). All
other general chemicals were obtained and prepared as described in Chapter 3, Section 3.2.1. The
naphthol stock solution was prepared by drying the naphthol using compressed air in order to
remove the ethanol. Then, PBS was added to obtain a concentration of 1 piCi/mL, and the
solution was 0.02-pm filtered.
Intact and tape-stripped skin samples were mounted into clean, dry Franz diffusion cells.
12 mL of PBS was added to the receiver chambers, and 0.5 mL of naphthol donor solution was
added to the donor chambers. Diffusion experiments were conducted for 2 hours at room
temperature (25*C) and under occluded conditions by sealing the donor chambers with parafilm.
The donor solutions were replaced every 30 minutes in order to maintain a constant donor
concentration. The receiver solutions were magnetically stirred at 500 RPM.
1-mL samples were withdrawn from the receiver chambers at 10-minute intervals from
60 to 110 minutes after the start of the experiment. Each receiver solution sample was
immediately replaced with an equal volume of PBS. After mixing each sample with 15 mL of
Hionic-Fluor scintillation cocktail, the radioactivity of the samples was measured using a Tri-
Carb 2810TR liquid scintillation analyzer (PerkinElmer, Waltham, Massachusetts). These data
were utilized to calculate the concentration of naphthol in the receiver chamber from 60 to 110
minutes, taking into account the replacement of the receiver samples and the background
radioactivity [28]. The data were analyzed using the methods described in Chapter 3, Section
3.2.9.
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6.3.2 RESULTS AND DISCUSSION
The stratum corneum is widely regarded as the primary barrier to transdermal diffusion.
However, after treating the skin with US/SLS, it was not clear whether the stratum corneum or
the hydrophilic epidermis is the primary diffusion barrier to hydrophobic permeants. Therefore,
the permeation of naphthol through US/SLS-treated intact and tape-stripped skin was compared.
As shown in FIGURE 6-2, naphthol diffused through tape-stripped skin at a significantly faster
rate than through intact skin. There is a statistically significant difference between the naphthol
concentrations at each time point between 60 and 110 minutes. Furthermore, there is a
statistically significant difference between the slopes of the linear regressions fitted to the data
shown in FIGURE 6-2. These results indicate that the stratum corneum remains a significant
diffusion barrier to hydrophobic permeants after US/SLS treatment.
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FIGURE 6-2: Comparison of naphthol permeation through US/SLS-treated intact skin and tape-
stripped skin. The data points are the mean of n replicates: n = 3 for intact skin and n = 7 for
tape-stripped skin. Error bars indicate 95% confidence intervals. The dashed lines represent the
linear regressions fitted to each data set. The corresponding linear regression parameters are
shown in the figure.
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